<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72116</article-id><article-id pub-id-type="doi">10.7554/eLife.72116</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Protein kinase Cδ is essential for the IgG response against T-cell-independent type 2 antigens and commensal bacteria</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-246166"><name><surname>Fukao</surname><given-names>Saori</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246167"><name><surname>Haniuda</surname><given-names>Kei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246168"><name><surname>Tamaki</surname><given-names>Hiromasa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-127111"><name><surname>Kitamura</surname><given-names>Daisuke</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5195-0474</contrib-id><email>kitamura@rs.tus.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Cancer Cell Biology, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science</institution><addr-line><named-content content-type="city">Noda</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Senior Editor</role><aff><institution>Yale School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e72116</elocation-id><history><date date-type="received" iso-8601-date="2021-07-12"><day>12</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-21"><day>21</day><month>10</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-07-20"><day>20</day><month>07</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.07.20.453051"/></event></pub-history><permissions><copyright-statement>© 2021, Fukao et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Fukao et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72116-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-72116-figures-v2.pdf"/><abstract><p>Antigens (Ags) with multivalent and repetitive structure elicit IgG production in a T-cell-independent manner. However, the mechanisms by which such T-cell-independent type-2 (TI-2) Ags induce IgG responses remain obscure. Here, we report that B-cell receptor (BCR) engagement with a TI-2 Ag but not with a T-cell-dependent (TD) Ag was able to induce the transcription of <italic>Aicda</italic> encoding activation-induced cytidine deaminase (AID) and efficient class switching to IgG3 upon costimulation with IL-1 or IFN-α in mouse B cells. TI-2 Ags strongly induced the phosphorylation of protein kinase C (PKC)δ and PKCδ mediated the <italic>Aicda</italic> transcription through the induction of BATF, the key transcriptional regulator of <italic>Aicda</italic>. In PKCδ-deficient mice, production of IgG was intact against TD Ag but abrogated against typical TI-2 Ags as well as commensal bacteria, and experimental disruption of the gut epithelial barrier resulted in fatal bacteremia. Thus, our results have revealed novel molecular requirements for class switching in the TI-2 response and highlighted its importance in homeostatic commensal-specific IgG production.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>When the human body faces a potentially harmful microorganism, the immune system responds by finding and destroying the pathogen. This involves the coordination of several different parts of the immune system. B cells are a type of white blood cell that is responsible for producing antibodies: large proteins that bind to specific targets such as pathogens. B cells often need help from other immune cells known as T cells to complete antibody production.</p><p>However, T cells are not required for B cells to produce antibodies against some bacteria. For example, when certain pathogenic bacteria coated with a carbohydrate called a capsule – such as pneumococcus, which causes pneumonia, or salmonella – invade our body, B cells recognize a repetitive structure of the capsule using a B-cell antigen receptor. This recognition allows B cells to produce antibodies independently of T cells. It is unclear how B cells produce antibodies in this situation or what proteins are required for this activity.</p><p>To understand this process, Fukao et al. used genetically modified mice and their B cells to study how they produce antibodies independently of T cells. They found that a protein called PKCδ is critical for B cells to produce antibodies, especially of an executive type called IgG, in the T-cell-independent response. PKCδ became active when B cells were stimulated with the repetitive antigen present on the surface of bacteria like salmonella or pneumococcus. Mice that lack PKCδ were unable to produce IgG independently of T cells, leading to fatal infections when bacteria reached the tissues and blood.</p><p>Understanding the mechanism behind the T cell-independent B cell response could lead to more effective antibody production, potentially paving the way for new vaccines to prevent fatal diseases caused by pathogenic bacteria.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>immune response</kwd><kwd>B cells</kwd><kwd>TI-2</kwd><kwd>class switching</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>Grant-in-Aid for Early-Career Scientists 19K16700</award-id><principal-award-recipient><name><surname>Fukao</surname><given-names>Saori</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Protein kinase Cδ, a kinase downstream of B-cell antigen receptor, is found to be essential for class switching to and production of IgG in the T-cell-independent type 2 immune response and for regulation of gut-residing bacteria.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Ag-specific antibody production is essential for humoral immunity. After T-cell-dependent (TD) antigen (Ag) exposure, B cells are activated by interacting with cognate T cells and then proliferate, undergo class switching, and differentiate into plasma cells (PCs) and memory cells. In contrast, T-cell-independent (TI) Ags activate B cells without cognate help of T cells. TI type 1 (TI-1) Ags engage Toll-like receptors (TLRs) in addition to the B-cell receptor (BCR) whereas TI-2 Ags extensively crosslink the BCR because of their highly repetitive structure (<xref ref-type="bibr" rid="bib34">Mond et al., 1995</xref>). In addition, some help from non-T cells, such as dendritic cells and innate lymphoid cells, may support B cells in a TI response (<xref ref-type="bibr" rid="bib28">Magri et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Balázs et al., 2002</xref>). Following activation, TI Ags induce proliferation, class switching, and antibody production by B cells. TI-2 Ags are large multivalent molecules, such as bacterial capsular polysaccharides and viral capsids, and thus antibody production against polysaccharides by the TI-2 response confers protection against disease (<xref ref-type="bibr" rid="bib34">Mond et al., 1995</xref>; <xref ref-type="bibr" rid="bib26">Lesinski and Westerink, 2001</xref>). To date, however, the mechanism of B-cell activation in the TI-2 response is poorly understood as compared to that in TD and TI-1 responses.</p><p>Engagement of the BCR by Ag activates various signaling cascades and promotes B-cell survival, proliferation and differentiation. The antibody production in a TI-2 response, but not in a TD response, depends upon proximal BCR signaling molecules such as Btk and BLNK (<xref ref-type="bibr" rid="bib20">Khan et al., 1995</xref>; <xref ref-type="bibr" rid="bib61">Xu et al., 2000</xref>; <xref ref-type="bibr" rid="bib13">Fruman et al., 2000</xref>), suggesting that BCR signaling plays a more critical role for B-cell activation in a TI-2 response than in a TD response. Given the highly repetitive structure of TI-2 Ags and the high demands for BCR signaling in TI-2 responses, TI-2 Ags seem to induce BCR signaling and the subsequent response more strongly than TD Ags. However, such functional differences between TD Ags and TI-2 Ags have not been investigated.</p><p>Class (isotype) switching of the immunoglobulin (Ig) on B cells from IgM to either IgG, IgE, or IgA is caused by selective recombination of Igh constant region (C<sub>H</sub>) genes, namely class-switch recombination (CSR). Selection of the C<sub>H</sub> gene to be recombined is determined by T-cell-derived cytokines in the TD response but the mechanism in the TI-2 response is not clear. Immunization with TI-2 Ags, including NP-Ficoll and bacterial polysaccharides, predominantly elicits IgG3 (<xref ref-type="bibr" rid="bib41">Perlmutter et al., 1978</xref>; <xref ref-type="bibr" rid="bib52">Slack et al., 1980</xref>; <xref ref-type="bibr" rid="bib45">Rubinstein and Stein, 1988</xref>) and IgG3 is required for protection against pneumococcal infection (<xref ref-type="bibr" rid="bib30">McLay et al., 2002</xref>). CSR absolutely requires activation-induced cytidine deaminase (AID) (<xref ref-type="bibr" rid="bib35">Muramatsu et al., 2000</xref>). AID deaminates deoxycytidine and introduces DNA double strand breaks (DSBs) in the switch (S) regions lying 5′ of the Cμ gene and the other targeted C<sub>H</sub> gene by triggering the DNA repair machinery (<xref ref-type="bibr" rid="bib54">Stavnezer et al., 2008</xref>). CSR proceeds through looping-out deletion of the DNA segment intervening between Sμ and the other S region from the chromosome and religation of the DSB-free ends in the two S regions. Consequently, it leads to replacement of the Cμ gene with a different C<sub>H</sub> gene downstream of the variable region exon in the <italic>Igh</italic> locus.</p><p>In a TD immune response, stimulation with CD40L and cytokines, such as IL-4 and TGFβ, induce the expression of AID and subsequent CSR in the B cell (<xref ref-type="bibr" rid="bib58">Vaidyanathan et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Dedeoglu et al., 2004</xref>), while signaling through TLRs, BCR, and TACI induce the expression of AID and CSR in a TI-1 response (<xref ref-type="bibr" rid="bib62">Xu et al., 2012</xref>). On the other hand, the signaling and molecular demands for the induction of AID and CSR in the TI-2 response are far less understood, presumably due to the lack of in vitro studies that mimic a TI-2 response. Although TACI is required for IgG production in a TI-2 response (<xref ref-type="bibr" rid="bib59">von Bülow et al., 2001</xref>), stimulation of TACI alone induces the expression of AID and IgG production only modestly (<xref ref-type="bibr" rid="bib6">Castigli et al., 2005</xref>). Therefore, signaling through other receptors besides TACI seems to be required. As antibody production itself is disrupted in mice lacking proximal BCR signaling molecules (<xref ref-type="bibr" rid="bib20">Khan et al., 1995</xref>; <xref ref-type="bibr" rid="bib61">Xu et al., 2000</xref>), the requirement of BCR signaling and the downstream molecules for CSR remain unclear. Here, we report our finding that stimulation of the BCR with NP-Ficoll, a typical TI-2 Ag, triggered IgG CSR in the presence of secondary stimulation by IL-1, IFNα, or TLR ligands in vitro and that protein kinase C (PKC)δ is critical for the Ag-mediated upregulation of AID and IgG production in the TI-2 response.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A TI-2 Ag induces B-cell proliferation and potentiates CSR to IgG</title><p>Considering the unique structure of TI-2 Ags, it is plausible that the engagement of the BCR with TI-2 Ags and TD Ags differently induces downstream signaling that leads to B-cell activation, although this idea has not been tested properly so far. We tested this in vitro by stimulating NP-specific B cells with the TD Ag NP-CGG or the TI-2 Ag NP-Ficoll to compare their ability to induce signaling, proliferation, and antibody production. NP-specific B cells were prepared from <italic>Igk<sup>−/−</sup></italic> mice (expressing only λ isotype light chain) carrying a <italic>V<sub>H</sub> B1-8</italic> knock-in gene encoding a V<sub>H</sub> region which binds to NP when coupled with a λ light chain. Although NP-CGG induced little proliferation and no IgM production, NP-Ficoll induced strong proliferation and IgM production, whereas neither induced IgG production (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Thus, although NP-Ficoll alone can strongly activate B cells, additional stimulation seemed to be required for induction of class switching, similar to a previous report that anti-δ mAb/dextran and TLR ligands synergistically induced AID and CSR (<xref ref-type="bibr" rid="bib42">Pone et al., 2012</xref>). Indeed, NP-Ficoll induced IgG production, generation of IgG<sup>+</sup> cells and <italic>Aicda</italic> transcription in the presence of TLR ligands, LPS, R-848, or CpG, while NP-CGG did so marginally (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A-C</xref>). Besides TI-1 Ags, such as TLR ligands, we sought to identify costimulating molecules that induce class switching in the TI-2 response, some of which were suggested previously (<xref ref-type="bibr" rid="bib28">Magri et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Balázs et al., 2002</xref>). Since IgG3 is the most dominant class-switched Ig isotype produced in a TI-2 response, we screened various cytokines for their ability to promote the production of IgG3 in the presence of NP-Ficoll, and identified IL-1α, IL-1β, and IFNα as efficient costimuli for IgG3 production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref> and <xref ref-type="fig" rid="fig1">Figure 1C</xref>). These cytokines, together with NP-Ficoll, induced generation of IgG3<sup>+</sup> cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), as well as IgG1<sup>+</sup> and IgG2b<sup>+</sup> cells to a lesser extent (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). In the presence of these cytokines, NP-Ficoll was far more potent than NP-CGG for IgG3 production, IgG3<sup>+</sup> cell generation, Sµ-Sγ3 CSR (detectable as the Iγ3-Cµ transcript from the switch circle DNA) (<xref ref-type="bibr" rid="bib62">Xu et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Kinoshita et al., 2001</xref>), and the induction of <italic>Aicda</italic> transcription (<xref ref-type="fig" rid="fig1">Figure 1C–E</xref>). NP-Ficoll or each of these cytokines alone could not induce those responses (<xref ref-type="fig" rid="fig1">Figure 1C–E</xref>). Collectively, these results indicate that BCR signaling elicited by TI-2 Ag engagement is pivotal for the TI-2 B-cell response, namely induction of proliferation and antibody production, as well as potentiation of CSR to IgG.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>T-cell-independent type-2 (TI-2) antigen (Ag) distinctively induces B-cell activation and class-switch recombination (CSR) to IgG in vitro.</title><p>(<bold>A and B</bold>) Naive B cells purified from the spleen of <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> mice were stimulated with NP-CGG or NP-Ficoll. (<bold>A</bold>) <sup>3</sup>H-thymidine incorporation on day 3. (<bold>B</bold>) IgM and IgG concentrations in the culture supernatants on day 3. (<bold>C–E</bold>) <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells were stimulated with none (–), NP-CGG, or NP-Ficoll and IL-1α, IL-1β, or IFNα, as indicated. (<bold>C</bold>) Enzyme-linked immunosorbent assay (ELISA) of IgG3 in the culture supernatant on day 3. AU, arbitrary units. (<bold>D</bold>) Representative flow cytometric plots on day 3 with the numbers indicating percentages of IgG3<sup>+</sup> B cells (top). The frequencies of IgG3<sup>+</sup> cells among the B cells (bottom). (<bold>E</bold>) quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis of the circle Iγ3-Cµ and <italic>Aicda</italic> transcripts on day 2. Data are means ± standard deviations (SDs) of two (<bold>B and C</bold>), two to three (<bold>D</bold>), or three (<bold>A</bold>) biological replicates or three technical replicates (<bold>E</bold>). The data are representative of at least three (<bold>A and B</bold>) or two (<bold>C–E</bold>) independent experiments. *p &lt; 0.05; ***p &lt; 0.001; ****p &lt; 0.0001; p values were calculated by one- (<bold>B</bold>) or two (<bold>C and D</bold>)-way analysis of variance (ANOVA) with Tukey’s test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1">Figure 1A–E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>T-cell-independent type-2 (TI-2) antigen (Ag) induces the generation of IgG<sup>+</sup> cells in the presence of secondary stimulation.</title><p>(<bold>A–C</bold>) <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> naive B cells were stimulated with nothing (–), NP-CGG, or NP-Ficoll in the presence of LPS, R-848, or CpG. (<bold>A</bold>) IgG concentration in the culture supernatants on day 3. (<bold>B</bold>) Representative flow cytometric plots on day 3 showing percentages of IgG<sup>+</sup> B cells. (<bold>C</bold>) qRT-PCR analysis of <italic>Aicda</italic> transcripts on day 2. (<bold>D and E</bold>) <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> naive B cells were stimulated with NP-Ficoll and each indicated cytokine. (<bold>D</bold>) IgG3 in the culture supernatants on day 4 titrated by enzyme-linked immunosorbent assay (ELISA). AU, arbitrary units. (<bold>E</bold>) Representative flow cytometric profiles of IgG1, IgG2b, IgG2c, and IgG3 on day 3 (left) and the ratio of B cells expressing these IgG subclasses estimated from the flow cytometry data (right). Data are means of three biological replicates (<bold>E</bold>), means ± standard deviations (SDs) of two biological replicates (<bold>A</bold>), or three technical replicates (<bold>C</bold>). The data are representative of two independent experiments. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001; ****p &lt; 0.0001; p values were calculated by two-way analysis of variance (ANOVA) with Tukey’s test (<bold>A</bold>).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A, C, D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>PKCδ is required for IgG production and AID expression induced by TI-2 Ag stimulation</title><p>By Western blot analyses for BCR signaling using NP-specific B cells, we noticed that NP-Ficoll-induced phosphorylation of PKCδ tyrosine 311 (Y311), indicative of activation of the kinase (<xref ref-type="bibr" rid="bib2">Balasubramanian et al., 2006</xref>), more strongly than NP-CGG (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). PKCδ belongs to a novel PKC subfamily (<xref ref-type="bibr" rid="bib48">Salzer et al., 2016</xref>), whose function in the immune response remains elusive. Thus, we analyzed the role of PKCδ in the TI-2 response using PKCδ-deficient (<italic>Prkcd<sup>−/−</sup></italic>) mice. B cells from <italic>Prkcd<sup>−/−</sup></italic> mice normally proliferate and produce IgM when stimulated with NP-Ficoll alone (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, B</xref>). Upon costimulation with NP-Ficoll and IL-1α, IL-1β, and IFNα, <italic>Prkcd<sup>−/−</sup></italic> B cells produced comparable levels of IgM but markedly reduced levels of IgG3 compared to <italic>Prkcd<sup>+/+</sup></italic> cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). As class switching occurs along with cell division (<xref ref-type="bibr" rid="bib10">Deenick et al., 1999</xref>), we analyzed the frequency of IgG3<sup>+</sup> cells at each cell division using B cells labeled with CellTrace Violet (CTV). While cell division was almost equivalent between these cells after costimulation with any of the cytokines and NP-Ficoll (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), the frequencies of IgG3<sup>+</sup> cells barely increased at any points of cell division in <italic>Prkcd</italic><sup>−/−</sup> cells in contrast to <italic>Prkcd</italic><sup>+/+</sup> cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Therefore, PKCδ is necessary for generation of IgG3<sup>+</sup> cells regardless of cell division. Accordingly, <italic>Igh</italic> locus CSR to IgG3 assessed by the circle Iγ3-Cµ transcript and the expression of <italic>Aicda</italic> transcripts were attenuated in <italic>Prkcd<sup>−/−</sup></italic> B cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Collectively, these results suggest that PKCδ mediates the expression of AID and class switching to IgG3 induced by BCR stimulation with TI-2 Ag and IL-1/IFNα costimulation.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Impaired T-cell-independent type-2 (TI-2) antigen (Ag)-mediated class-switch recombination (CSR) in protein kinase C (PKC)δ-deficient B cells.</title><p>(<bold>A</bold>) Immunoblot analysis of the indicated molecules in <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells stimulated with NP-CGG or NP-Ficoll for the indicated time periods. (<bold>B–D</bold>) <italic>Prkcd</italic><sup>+<italic>/+</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> or <italic>Prkcd<sup>−/−</sup> Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells were stimulated with NP-Ficoll and IL-1α, IL-1β, or IFNα. The B cells were labeled with CellTrace Violet (CTV) before culture in C. (<bold>B</bold>) Enzyme-linked immunosorbent assay (ELISA) of IgM and IgG3 in the culture supernatants on day 5. AU, arbitrary units. (<bold>C</bold>) Representative flow cytometric plots of the B cells on day 3 showing percentages of IgG3<sup>+</sup> B cells (left). The frequencies of IgG3<sup>+</sup> cells at each cell division number (right). (<bold>D</bold>) qRT-PCR analysis of the circle Iγ3-Cµ and <italic>Aicda</italic> transcripts on day 2. Data are means ± standard deviations (SDs) of two (<bold>B</bold>) or three (<bold>C</bold>) biological replicates or three technical replicates (<bold>D</bold>). The data are representative of at least three (<bold>A and B</bold>) or two (<bold>C and D</bold>) independent experiments. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001; p values were calculated by unpaired multiple <italic>t</italic>-test (<bold>B and C</bold>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2B–D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig2-data2-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig2-data3-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig2-data4-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72116-fig2-data5-v2.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>In vitro response of protein kinase C (PKC)δ-deficient B cells.</title><p>(<bold>A and B</bold>) <italic>Prkcd</italic><sup>+<italic>/+</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> or <italic>Prkcd</italic><sup><italic>−/−</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> naive B cells were cultured with medium alone (–) or NP-Ficoll. (<bold>A</bold>) <sup>3</sup>H-thymidine incorporation on day 3. (<bold>B</bold>) IgM concentration in the culture supernatant on day 4. (<bold>C</bold>) The histogram of CellTrace Violet (CTV) in cells analyzed in <xref ref-type="fig" rid="fig2">Figure 2C</xref>. (<bold>D–G</bold>) <italic>Prkcd</italic><sup>+<italic>/+</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> or <italic>Prkcd</italic><sup>−<italic>/−</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> naive B cells were cultured with NP-Ficoll and LPS, R-848, or CpG (<bold>D and E</bold>) or LPS, R-848, or CpG alone (<bold>F and G</bold>). (<bold>D and F</bold>) IgM and IgG concentrations in the culture supernatants on day 3. (<bold>E and G</bold>) qRT-PCR analysis of <italic>Aicda</italic> transcripts on day 2. Data are means ± standard deviation (SD) of three (<bold>A</bold>) or two to three (<bold>B</bold>), and two (<bold>D and F</bold>) biological replicates, or three technical replicates (<bold>E and G</bold>). The data are representative of two independent experiments. *p &lt; 0.05; ***p &lt; 0.001; p values were calculated by unpaired multiple <italic>t</italic>-test (<bold>A, B, and D</bold>).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, B, D-G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig2-figsupp1-v2.tif"/></fig></fig-group><p><italic>Prkcd<sup>−/−</sup></italic> B cells also exhibited defects in the production of IgG and <italic>Aicda</italic> transcripts, but normal IgM production, upon stimulation with NP-Ficoll and TLR ligands (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D, E</xref>), but no defects in the production of IgM, IgG, and <italic>Aicda</italic> transcripts, upon stimulation with TLR ligands alone (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F, G</xref>). Together with the above results, PKCδ appears to be selectively required for TI-2-Ag-mediated BCR signaling to potentiate CSR to produce IgG.</p></sec><sec id="s2-3"><title>PKCδ mediates IgG production in a TI-2 response in vivo</title><p>We next evaluated the contribution of PKCδ to IgG production in a TI-2 immune response using mice carrying loxP-flanked <italic>Prkcd</italic> alleles and <italic>Cd19</italic>-cre allele that lack <italic>Prkcd</italic> specifically in B cells (referred to herein as <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic>). We first examined the cellularity of mature B-cell subpopulations in such mice and their control (<italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic>). The numbers of follicular and marginal zone B cells in spleens were comparable between these mice, whereas those of splenic and peritoneal B1 cell populations were slightly increased in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Thus, PKCδ is dispensable for the development of B cells, as previously described (<xref ref-type="bibr" rid="bib31">Mecklenbräuker et al., 2002</xref>; <xref ref-type="bibr" rid="bib33">Miyamoto et al., 2002</xref>).</p><p>To analyze the role of PKCδ in a TI-2 response, we immunized <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> and the control mice with NP-Ficoll. Although the production of serum anti-NP IgM was slightly enhanced in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice, that of anti-NP IgG3 was severely suppressed (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), and so was that of anti-NP IgG1, IgG2b, and IgG2c (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We then analyzed PCs in the spleen 1 week after immunization. Among the NP-specific PCs, the proportion and the number of IgG3- and IgG2b-producing PCs were severely decreased in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice compared to the control mice, whereas the number of IgM<sup>+</sup> PCs was comparable between the two groups (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Therefore, PKCδ is required for the generation of IgG<sup>+</sup> PCs and the subsequent production of IgG in the TI-2 response.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Protein kinase C (PKC)δ is required for IgG production in T-cell-independent type-2 (TI-2) response in vivo.</title><p>(<bold>A–C</bold>) <italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic> and <italic>Cd19<sup>cre/+</sup> Prkcd<sup>f/f</sup></italic> mice were immunized with NP-Ficoll. (<bold>A</bold>) Enzyme-linked immunosorbent assay (ELISA) of serum anti-NP IgM and IgG3 at the indicated weeks. (<bold>B</bold>) ELISA of serum anti-NP IgG1, IgG2b, and IgG2c at 2 weeks after immunization. (<bold>C</bold>) Representative flow cytometric plots of the spleen cells on day 7 after immunization. The numbers indicate the percentage of cells in each gate (left). The frequencies of IgM<sup>+</sup>, IgG2b<sup>+</sup>, and IgG3<sup>+</sup> cells among NP-binding plasma cells (PCs; NP<sup>+</sup> CD138<sup>+</sup>; middle) and the numbers of such cells per 1 × 10<sup>7</sup> total lymphocytes (right) are plotted. (<bold>D</bold>) ELISA of anti-PPS3 IgM and IgG3 in the serum of <italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic> and <italic>Cd19<sup>cre/+</sup> Prkcd<sup>f/f</sup></italic> mice at the indicated weeks after immunization with PPS3. Results are presented in AU, arbitrary units (<bold>A, B, and D</bold>). Small horizontal bars are the means of six to eight (A and B), five (<bold>C</bold>), and eight (<bold>D</bold>) biological replicates. Each symbol represents an individual mouse. The data are representative of three (<bold>A and C</bold>) or two (<bold>B and D</bold>) independent experiments. *p &lt; 0.05; **p &lt; 0.01; ****p &lt; 0.0001; p values were calculated by unpaired multiple (<bold>A, C, and D</bold>) or two-tailed unpaired Welch’s <italic>t</italic>-test (<bold>B</bold>).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3">Figure 3A–D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>B-cell development and T-cell-dependent (TD) response of protein kinase C (PKC)δ-deficient mice.</title><p>(<bold>A</bold>) Flow cytometric analysis of spleen cells and peritoneal cavity cells of <italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic> and <italic>Cd19<sup>cre/+</sup> Prkcd <sup>fl/fl</sup></italic> mice. Gating strategy of follicular B cells (Fo B; CD19<sup>+</sup>CD43<sup>−</sup>CD21<sup>+</sup>CD23<sup>+</sup>), marginal zone B cells (MZ B; CD19<sup>+</sup>CD43<sup>−</sup>CD21<sup>high</sup>CD23<sup>low</sup>), B1a cells (CD19<sup>+</sup>CD43<sup>+</sup>CD5<sup>+</sup>), and B1b cells (CD19<sup>+</sup>CD43<sup>+</sup>CD5<sup>−</sup>) in the spleen is shown (left). The numbers of Fo B, MZ B, B1a, and B1b cells in spleen (middle) and peritoneal cavity (right) are plotted. (<bold>B</bold>) Enzyme-linked immunosorbent assay (ELISA) of anti-NP IgM, IgG1, and IgG3 in the sera of <italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic> and <italic>Cd19<sup>cre/+</sup> Prkcd <sup>fl/fl</sup></italic> mice at indicated weeks after immunization with NP-CGG in alum. AU, arbitrary units. Small horizontal bars are the means of four (<bold>A</bold>) or six (<bold>B</bold>) biological replicates. Each symbol represents an individual mouse. The data are representative of three (<bold>A</bold>) or two (<bold>B</bold>) independent experiments. *p &lt; 0.05; ****p &lt; 0.0001; p values were calculated by unpaired multiple <italic>t-</italic>test.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig3-figsupp1-v2.tif"/></fig></fig-group><p>The capsular polysaccharides of <italic>Streptococcus pneumoniae</italic>, such as pneumococcal polysaccharide serotype 3 (PPS3), are also classified as TI-2 Ags, and immunization with PPS3 is known to induce an Ag-specific IgG3 response (<xref ref-type="bibr" rid="bib30">McLay et al., 2002</xref>). Thus, we next immunized <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> and control mice with PPS3. Although early production of anti-PPS3 IgM was modestly enhanced in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice, production of anti-PPS3 IgG3 was ablated in these mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Thus, PKCδ appears to be generally required for IgG production in response to a variety of TI-2 Ags.</p><p>We next assessed whether PKCδ is also required for IgG production in a TD response. After immunization with NP-CGG, the production of anti-NP IgM was transiently enhanced in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice at 1 week, whereas anti-NP IgG1 and IgG3 titers were normal in these mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). These data indicated that PKCδ signaling is required for IgG production in a TI-2 response, but not in a TD response.</p></sec><sec id="s2-4"><title>PKCδ mediates class switching through induction of AID in a TI-2 response in vivo</title><p>We next assessed whether PKCδ mediates IgG production through class switching in an in vivo TI-2 response. To discriminate Ag-specific B-cell responses, we transferred CTV-labeled naive B cells from <italic>B1-8<sup>hi</sup></italic> CD45.1 mice into C57BL/6 (B6) mice, which were immunized with NP-Ficoll on the next day and analyzed by flow cytometry 3 days later. About 30% of the splenic donor cells were IgG3<sup>+</sup> in the mice transferred with control B cells, whereas only about 3% were IgG3<sup>+</sup> in recipients of <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> B cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). IgG3<sup>+</sup> cells emerged at the second cell division and their frequency was increased as the cell division proceeded in the cells of control mice, whereas the frequency of IgG3<sup>+</sup> cells was extremely low in the cells of <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice at any point of cell division (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Thus, PKCδ mediates the generation of IgG3<sup>+</sup> cells in a manner unrelated to cell division.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Protein kinase C (PKC)δ signaling promotes IgG class switching by inducing activation-induced cytidine deaminase (AID).</title><p>(<bold>A and B</bold>) B cells purified from <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> or <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> mice were labeled with CellTrace Violet (CTV) and transferred into B6 mice, which were immunized with NP-Ficoll on the next day. Spleen cells were analyzed 3 days later. (<bold>A</bold>) Representative flow cytometric plots of the spleen cells with the numbers indicating percentages of the cells within the neighboring gates (left). The frequency of IgG3<sup>+</sup> cells among whole donor B cells (CD45.1<sup>+</sup> CD19<sup>+</sup> CD138<sup>–</sup>) (middle) and at each cell division number (right) are shown. (<bold>B</bold>) qRT-PCR analysis of the indicated transcripts in the donor B cells collected as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. (<bold>C</bold>) <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> or <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> B cells transduced with an empty vector (Ev) or vectors expressing AID or PKCδ were transferred into B6 mice that had been immunized with NP-Ficoll on the previous day as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>. Representative flow cytometry plots of the donor cells transduced with the vectors (CD45.1<sup>+</sup>GFP<sup>+</sup>, gated as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) (left) and the frequency of IgG3<sup>+</sup> cells among the CD45.1<sup>+</sup>GFP<sup>+</sup> cells (right) on day 3 after transfer. Small horizontal bars are the means of five (<bold>A</bold>) or six to nine (<bold>C</bold>) biological replicates. Each symbol represents an individual mouse (A, middle; <bold>C</bold>). The symbols are the means of five biological replicates (A, right). Data are means ± standard deviations (SDs) of three technical replicates pooled from five mice (<bold>B</bold>). The data are representative of three (<bold>A</bold>) or two (<bold>B</bold>) independent experiments or is pooled from two independent experiments (<bold>C</bold>). ns, not significant (p &gt; 0.05); **p &lt; 0.01; ****p &lt; 0.0001; p values were calculated by unpaired multiple <italic>t</italic>-test (<bold>A</bold>) or one-way analysis of variance (ANOVA) with Tukey’s test (<bold>C</bold>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4A–C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Gating strategies.</title><p>(<bold>A</bold>) Sorting strategy for donor B cells used in <xref ref-type="fig" rid="fig4">Figure 4B</xref>. The starting population was spleen cells of B6 mice transferred with <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> or <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic>, CD45.1<sup>+</sup> B cells and immunized with NP-Ficoll 3 days previously. CD45.1<sup>+</sup> cells were enriched by a MACS system (left) and then donor B cells (CD45.1<sup>+</sup>CD19<sup>+</sup>CD138<sup>−</sup>) were further sorted by flow cytometry (right). (<bold>B and C</bold>) Strategy for retrovirus (Rv) transduction and the analysis of the TI-2 response (B, left). B cells collected from <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> or <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> mice immunized with NP-Ficoll 1 day previously were infected with Rv and cultured for 1 day. Some Rv-transduced cells were further cultured in medium for 6 hr and analyzed by flow cytometry. Representative data of the cells transduced with pMXs-IRES-GFP empty vector (Ev) is shown (B, right). Other Rv-transduced cells were transferred into B6 mice that had been immunized with NP-Ficoll on the previous day. Spleen cells of recipient mice were analyzed or used for cell sorting 3 or 4 days later. Gating strategy of donor cells transduced with vectors (CD45.1<sup>+</sup> GFP<sup>+</sup>) and the expression profile of IgG3 are shown (C, left). After the enrichment of CD45.1<sup>+</sup> cells by a MACS system, the vector-transduced donor B cells (CD45.1<sup>+</sup> GFP<sup>+</sup> CD19<sup>+</sup> CD138<sup>–</sup>) were sorted as shown (C, right). The data are representative of at least three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig4-figsupp1-v2.tif"/></fig></fig-group><p>We next analyzed molecular events associated with CSR in sorted donor cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). The amounts of the Iγ3-Cµ circle transcripts and the Iµ-Cγ3 early postswitch transcripts were far less in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> B cells compared to control cells, indicating fewer CSR events in the former in vivo (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The expression of Iµ-Cµ and Iγ3-Cγ3 germline transcripts was comparable between the <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> B cells and the control cells, whereas the expression of <italic>Aicda</italic> was substantially reduced in the former (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These results indicate that PKCδ mediates CSR to IgG3 through upregulation of AID mRNA, but not through the activation of <italic>Ig</italic> gene S regions in B cells responding to TI-2 Ags in vivo.</p><p>To examine whether the reduction of AID is a primary reason for the impaired generation of IgG3<sup>+</sup> cells from PKCδ-deficient B cells, we transduced AID into in vivo primed <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup> B1-8<sup>hi</sup></italic> B cells and transferred them into B6 mice that had been immunized with NP-Ficoll 1 day previously (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). The reconstitution of AID expression restored IgG3 class switching to a frequency comparable to the same cells reconstituted with PKCδ (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref> and <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Collectively, these results indicate that PKCδ mediates class switching to IgG3 by upregulating the expression of AID in the TI-2 response.</p></sec><sec id="s2-5"><title>PKCδ upregulates the transcription of <italic>Aicda</italic> through BATF</title><p>It has been shown that expression of <italic>Aicda</italic> gene is regulated by various transcriptional factors (<xref ref-type="bibr" rid="bib58">Vaidyanathan et al., 2014</xref>; <xref ref-type="bibr" rid="bib57">Tran et al., 2010</xref>; <xref ref-type="bibr" rid="bib8">Crouch et al., 2007</xref>). To assess the role of PKCδ in <italic>Aicda</italic> gene expression, we quantified expression levels of the genes encoding such transcription factors in PKCδ-sufficient and PKCδ-deficient B cells collected from mice immunized with NP-Ficoll. Among the genes tested, we found that the amount of <italic>Batf</italic> mRNA was markedly lower in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> B cells than in control cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The expression of BATF mRNA and protein was induced by in vitro stimulation with NP-Ficoll alone in PKCδ-sufficient B cells, but only marginally in PKCδ-deficient B cells (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>), whereas BATF expression was not induced by NP-CGG (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). IL-1α, IL-1β, or IFNα did not augment the phosphorylation of PKCδ nor induce <italic>Batf</italic> expression nor enhance the NP-Ficoll-induced <italic>Batf</italic> expression (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B-D</xref>). Collectively, these data indicate that PKCδ induces the expression of BATF downstream of the BCR in the TI-2 response.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Protein kinase C (PKC)δ regulates IgG class switching by upregulating BATF expression.</title><p>(<bold>A</bold>) qRT-PCR analysis of the transcripts of the indicated genes in <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> or <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> donor B cells (CD45.1<sup>+</sup>CD19<sup>+</sup>CD138<sup>−</sup>) purified as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref> from the recipient mice immunized with NP-Ficoll 3 days previously. Shown is the relative expression of each gene in <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup></italic> cells to that in <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup></italic> cells. (<bold>B</bold>) qRT-PCR analysis of <italic>Batf</italic> transcripts in <italic>Prkcd</italic><sup>+<italic>/+</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> or <italic>Prkcd<sup>−/−</sup> Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells cultured with medium alone (–) or with the indicated stimuli for 2 days. (<bold>C</bold>) Immunoblot analysis in <italic>Prkcd</italic><sup>+<italic>/+</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> or <italic>Prkcd<sup>−/−</sup> Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells stimulated with NP-Ficoll for the indicated times. (<bold>D and E</bold>) <italic>B1-8<sup>hi</sup></italic> B cells transduced with knockdown vectors for luciferase (shControl) or BATF (shBATF) were transferred into B6 mice that had been immunized with NP-Ficoll on the previous day as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>, and their spleen cells were analyzed on day 4 after transfer. (<bold>D</bold>) qRT-PCR analysis of <italic>Aicda</italic> and <italic>Batf</italic> transcripts in the vector-transduced donor B cells (CD45.1<sup>+</sup> GFP<sup>+</sup> CD19<sup>+</sup> CD138<sup>−</sup>) collected as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>. (<bold>E</bold>) Representative flow cytometric plots of the transduced donor cells with the numbers indicating the percentage of IgG3<sup>+</sup> cells (left) and the frequency of the IgG3<sup>+</sup> cells among such cells (right) gated as in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>. (<bold>F and G</bold>) <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup> B1-8 <sup>hi</sup></italic> B cells transduced with Ev or vectors expressing BATF or PKCδ were transferred into B6 mice that had been immunized with NP-Ficoll on the previous day, and their spleen cells were analyzed 3 days after transfer. (<bold>F</bold>) qRT-PCR analysis of <italic>Aicda</italic> transcripts in the vector-transduced donor B cells. (<bold>G</bold>) Representative flow cytometric plots of the transduced donor cells with the numbers indicating the percentage of IgG3<sup>+</sup> cells (left) and the frequency of the IgG3<sup>+</sup> cells among such cells (right). Data are means ± standard deviations (SDs) of three technical replicates (<bold>A, B, D, and F</bold>). Samples were pooled from five to eight mice (<bold>D and F</bold>). Small horizontal bars are the means of four (<bold>E</bold>) or eight to nine (<bold>G</bold>) biological replicates. Each symbol represents an individual mouse (<bold>E and G</bold>). The data are representative of two independent experiments (<bold>A–F</bold>) or are pooled from two independent experiments (<bold>G</bold>). ***p &lt; 0.001; ****p &lt; 0.0001; p values were calculated by two-tailed unpaired Student’s <italic>t</italic>-test (<bold>E</bold>) or one-way analysis of variance (ANOVA) with Tukey’s test (<bold>G</bold>).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5A, B and D–G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig5-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-data2-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-data3-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-data4-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5C</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72116-fig5-data5-v2.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The expression of BATF and the phosphorylation of protein kinase C (PKC)δ.</title><p>(<bold>A–C</bold>) Immunoblot analysis of <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells stimulated with the indicated reagents for the indicated times (<bold>A and C</bold>) or 5 min (<bold>B</bold>). (<bold>D</bold>) qRT-PCR analysis of <italic>Batf</italic> transcripts in <italic>Prkcd</italic><sup>+<italic>/+</italic></sup> <italic>Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> or <italic>Prkcd<sup>−/−</sup> Igk<sup>−/−</sup> B1-8<sup>flox/+</sup></italic> B cells cultured with the indicated reagents for 2 days. The data are representative of two independent experiments.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data1-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data2-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data3-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata4"><label>Figure 5—figure supplement 1—source data 4.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data4-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata5"><label>Figure 5—figure supplement 1—source data 5.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data5-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata6"><label>Figure 5—figure supplement 1—source data 6.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data6-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata7"><label>Figure 5—figure supplement 1—source data 7.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data7-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata8"><label>Figure 5—figure supplement 1—source data 8.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data8-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata9"><label>Figure 5—figure supplement 1—source data 9.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data9-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata10"><label>Figure 5—figure supplement 1—source data 10.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>.</title></caption><media mime-subtype="tif" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data10-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata11"><label>Figure 5—figure supplement 1—source data 11.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data11-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata12"><label>Figure 5—figure supplement 1—source data 12.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig5-figsupp1-data12-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig5-figsupp1-v2.tif"/></fig></fig-group><p>It was reported that BATF binds to a regulatory region of the <italic>Aicda</italic> gene to directly promote its expression and that IgG3 production against TNP-Ficoll was impaired in <italic>Batf<sup>−/−</sup></italic> mice (<xref ref-type="bibr" rid="bib19">Ise et al., 2011</xref>). Therefore, we next asked whether the defect of BATF expression is responsible for the suppression of AID expression and IgG3<sup>+</sup> cell generation in PKCδ-deficient mice. First, we knocked down BATF in <italic>B1-8<sup>hi</sup></italic> B cells and transferred them into mice immunized with NP-Ficoll. Both the expression of <italic>Aicda</italic> and the frequency of IgG3<sup>+</sup> cells were significantly decreased in BATF knockdown cells compared with the mock-transduced control cells (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Conversely, forced expression of BATF in <italic>B1-8<sup>hi</sup> Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> B cells partially but significantly restored <italic>Aicda</italic> expression and the generation of IgG3<sup>+</sup> cells in the recipient mice immunized with NP-Ficoll (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). Taken together, these data indicate that PKCδ mediates expression of AID and class switching to IgG3 through upregulation of BATF expression in B cells undergoing a TI-2 response.</p></sec><sec id="s2-6"><title>PKCδ is required for homeostatic antibacterial IgG3 production and protection against bacteremia</title><p>Recent works have revealed that commensal microbes induce an IgG response and confer protection against systemic bacterial infection (<xref ref-type="bibr" rid="bib63">Zeng et al., 2016</xref>). Among antibacterial IgG, IgG3 is most abundant and produced in a TI manner (<xref ref-type="bibr" rid="bib1">Ansaldo et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Koch et al., 2016</xref>). Therefore, we assessed the contribution of PKCδ in IgG-mediated antibacterial responses. To standardize the microbiota, we cohoused control and <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice over 4 weeks and serum antibodies against fecal bacteria were titrated. Production of serum antibacterial IgM, IgG1, and IgG2b was not changed significantly, but that of IgG3 was severely impaired in <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Antibacterial IgG2c was undetectable in both mouse groups (data not shown). Given that PKCδ was required for production of all IgG subclasses in the anti-NP TI-2 response (<xref ref-type="fig" rid="fig3">Figure 3</xref>), the PKCδ-independent production of antibacterial IgG1 and IgG2b may be attributable to TD responses, as reported for IgG1 (<xref ref-type="bibr" rid="bib1">Ansaldo et al., 2019</xref>), while antibacterial IgG3 is mainly produced by the TI-2 response.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Protein kinase C (PKC)δ is required for protective antibacterial IgG3 production.</title><p><italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic> and <italic>Cd19<sup>cre/+</sup> Prkcd<sup>f/f</sup></italic> mice were cohoused for at least 4 weeks and treated with 3 % dextran sodium sulfate (DSS) for 7 days. (<bold>A</bold>) Serum IgM, IgG1, IgG2b, and IgG3 against fecal bacteria after cohousing were quantified by enzyme-linked immunosorbent assay (ELISA). AU, arbitrary units. (<bold>B</bold>) Colony-forming unit (CFU) of aerobes and anaerobes in the blood 7 days after DSS treatment. (<bold>C</bold>) Kaplan–Meier survival plot of 16 (<italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic>) and 12 (<italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic>) mice at indicated days. Small horizontal bars are the means of 7 (<bold>A</bold>), or 15 (<italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic>) or 11 (<italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic>) in (<bold>B</bold>), biological replicates. Data were obtained from 16 (<italic>Cd19<sup>cre/+</sup> Prkcd<sup>+/+</sup></italic>) or 12 (<italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic>) mice in (<bold>C</bold>). Each symbol represents an individual mouse (<bold>A and B</bold>). The data are representative of two independent experiments (<bold>A</bold>) or pooled from two independent experiments (<bold>B and C</bold>). **p &lt; 0.01; ***p &lt; 0.001; p values were calculated by two-tailed unpaired Welch’s <italic>t</italic>-test (<bold>A</bold>), unpaired multiple <italic>t</italic>-test (<bold>B</bold>), or log-rank test (<bold>C</bold>).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6">Figure 6A and B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig6-v2.tif"/></fig><p>We further asked whether regulation of commensal bacteria is defective in the PKCδ-deficient mice. Dextran sodium sulfate (DSS) treatment is known to disrupt the gut epithelium and to allow intestinal bacteria to translocate throughout the body. Subsequently, it leads to fatal bacteremia in the absence of microbiota-specific IgG (<xref ref-type="bibr" rid="bib63">Zeng et al., 2016</xref>). After the treatment with DSS, <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice exhibited increased numbers of aerobic and anaerobic bacteria in the blood compared to control mice (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Accordingly, the mortality of <italic>Cd19<sup>cre/+</sup> Prkcdf<sup>f/f</sup></italic> mice was significantly higher than that of control mice (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Collectively, these results suggest that IgG3 production by a TI-2 response via PKCδ prevents lethal bacteremia.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Although previous reports showed that proximal BCR signal molecules such as BLNK or Btk are necessary for B-cell activation and subsequent IgM and IgG production in the TI-2 response in mice (<xref ref-type="bibr" rid="bib61">Xu et al., 2000</xref>; <xref ref-type="bibr" rid="bib12">Ellmeier et al., 2000</xref>), it was not clear whether there are any specific BCR signaling pathways inducing CSR. Here, we demonstrated that BCR stimulation with a TI-2 Ag (NP-Ficoll), but not a TD Ag (NP-CGG), both sharing the same BCR epitope, promoted transcription of <italic>Aicda</italic> and induced IgG3 CSR in the presence of a secondary stimulation. BCR engagement with a TI-2 Ag induced the phosphorylation of PKCδ and PKCδ was required for upregulation of BATF expression, thereby mediated the induction of <italic>Aicda</italic> transcription and subsequent CSR to the IgG subclasses (<xref ref-type="fig" rid="fig7">Figure 7</xref>). By contrast, PKCδ was dispensable for TI-2 Ag-mediated B-cell proliferation, IgM production, as well as for B-cell development and the TD response. Thus, we have found for the first time, as far as we know, a BCR signaling molecule that is selectively required for CSR in the TI-2 response.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Working model of the protein kinase C (PKC)δ-mediated induction of class-switch recombination (CSR) in the T-cell-independent type-2 (TI-2) response.</title><p>B-cell receptor (BCR) stimulation with a TI-2 antigen (Ag) activates PKCδ signaling and induces the expression of BATF, which works cooperatively with secondary signals induced by IL-1α/β, IFNα, or TLR ligands and drives the transcription of activation-induced cytidine deaminase (AID) to induce IgG CSR.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72116-fig7-v2.tif"/></fig><p>TI-2 Ags such as NP-Ficoll can induce antibody response in the absence of major histocompatibility complex class II-restricted T cell help or MyD88-mediated TLR receptor signaling (<xref ref-type="bibr" rid="bib15">Gavin et al., 2006</xref>; <xref ref-type="bibr" rid="bib18">Hou et al., 2011</xref>). Thus, it has been unclear whether any costimulation is necessary for B-cell activation in a TI-2 response. We demonstrated that NP-Ficoll, but not NP-CGG, was able to activate NP-specific naive B cells to induce proliferation, antibody production, and potentiation for CSR in vitro. Thus, despite sharing the same antigenic epitope (NP) at a similar average number per molecule, these Ags appear to elicit disparate BCR signal transduction. After Ag binding, the BCR is clustered and recruited to lipid microdomains, in which signaling proteins are localized that trigger B-cell activation signaling (<xref ref-type="bibr" rid="bib39">Niiro and Clark, 2002</xref>). Ag structure probably affects such BCR dynamics or membrane organization of signal components. Consistently, it was previously reported that a high-valency TI-2 Ag induces the formation of large BCR clusters in the lipid microdomains (<xref ref-type="bibr" rid="bib43">Puffer et al., 2007</xref>).</p><p>We have revealed that, in the TI-2 response, BCR-downstream signaling through PKCδ is critical for CSR and generation of IgG. PKCδ is known to control Ag-induced tolerance in immature B cells (<xref ref-type="bibr" rid="bib31">Mecklenbräuker et al., 2002</xref>; <xref ref-type="bibr" rid="bib27">Limnander et al., 2011</xref>). However, a possible alteration of the mature B-cell repertoire in PKCδ-deficient mice is not attributable to the defective class switching to IgG3, since the defect was obvious in the NP-Ficoll response by PKCδ-deficient, B1-8V<sub>H</sub>-knock-in B cells with a monoclonal anti-NP repertoire. Here, we demonstrated that PKCδ mediated the expression of AID to induce CSR. BCR engagement with a TI-2 Ag induced the expression of BATF via PKCδ and BATF was required for the transcription of the <italic>Aicda</italic> gene in a TI-2 response, as reported previously (<xref ref-type="bibr" rid="bib19">Ise et al., 2011</xref>). Forced expression of BATF in PKCδ-deficient B cells restored the expression of AID and IgG3 class switching significantly, but less effectively, than that of PKCδ itself. In this regard, various transcription factors have been reported to cooperatively induce the transcription of AID in the TD response (<xref ref-type="bibr" rid="bib58">Vaidyanathan et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Crouch et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Tran et al., 2010</xref>). Although we have not assessed the contribution of other transcription factors in the TI-2 response, since the expression of other candidate genes was intact in PKCδ-deficient B cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), PKCδ signaling might regulate other transcription factors in addition to BATF to fully upregulate the expression of AID to induce CSR in the TI-2 response.</p><p>PKCδ contains several phosphorylation sites, whose phosphorylation pattern affects its enzymatic activity and possibly the selection of downstream targets (<xref ref-type="bibr" rid="bib48">Salzer et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Steinberg, 2004</xref>). Although the phosphorylation of Thr 505 and Ser 647 of PKCδ is known to be important for its enzymatic activity, phosphorylation of these sites was constitutive in unstimulated naive B cells and did not increase after NP-Ficoll stimulation (data not shown). This observation and a previous report that PKCδ exerts proapoptotic activity in peripheral B cells through nuclear translocation, unless BAFF signaling reverses it (<xref ref-type="bibr" rid="bib32">Mecklenbräuker et al., 2004</xref>), indicate a constitutive PKCδ activity in B cells irrespective of Ag stimulation. Augmented IgM production after immunization with TI-2 as well as TD Ags in PKCδ-deficient mice (<xref ref-type="fig" rid="fig3">Figure 3A and D</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) may reflect the lack of the general proapoptotic function of PKCδ. On the other hand, phosphorylation of PKCδ at Tyr 311, shown here to be selectively augmented by TI-2 Ag stimulation, is known to alter its intracellular localization and the substrate specificity (<xref ref-type="bibr" rid="bib46">Rybin et al., 2004</xref>; <xref ref-type="bibr" rid="bib55">Steinberg, 2004</xref>) and to be involved in various cellular responses (<xref ref-type="bibr" rid="bib2">Balasubramanian et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Nakashima et al., 2008</xref>). Thus, to understand the mechanism of TI-2 Ag-specific BCR signaling that induces the expression of BATF and AID, it would be necessary to identify a specific substrate of the phosphorylated PKCδ at Tyr 311.</p><p>In contrast to TI-2 response, PKCδ was not required for IgG production in the TD response, like other proximal BCR molecules (<xref ref-type="bibr" rid="bib20">Khan et al., 1995</xref>; <xref ref-type="bibr" rid="bib61">Xu et al., 2000</xref>). In vitro stimulation with a TD Ag alone induced only a marginal level of phosphorylation of PKCδ and other signaling molecules (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and data not shown) and did not induce proliferation, IgM production, and the expression of BATF. Accordingly, we assume that the TD Ag-mediated BCR signaling cannot exceed an activation threshold to induce gene expression leading to functional B-cell response including class switching. Instead, other stimuli such as CD40L would meet the demand for B-cell activation in TD response. Supporting this view, it was reported that BCR signaling does not enhance the class switching induced by CD40 signaling (<xref ref-type="bibr" rid="bib42">Pone et al., 2012</xref>).</p><p>The synergistic effect of TLR and BCR on the induction of AID has been shown previously (<xref ref-type="bibr" rid="bib42">Pone et al., 2012</xref>). Here, we found that IL-1α/β, IFNα, and TLR ligands costimulate B cells with TI-2 Ag to induce <italic>Aicda</italic> expression and class switching to IgG3 and perhaps other IgG subclasses, while other cytokines tested barely induced IgG3 production in vitro. In the context of TD response, the recruitment of NF-κB and STAT6 to the 5′ upstream enhancer region of <italic>Aicda</italic> locus, in addition to BATF recruitment to the 3′ downstream region, is required for the transcription of <italic>Aicda</italic> (<xref ref-type="bibr" rid="bib57">Tran et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Vaidyanathan et al., 2014</xref>). Since the in vitro stimulation by TI-2 Ag induced the expression of BATF but not of <italic>Aicda</italic> without the additional stimulation<italic>,</italic> such costimulation may signal the recruitment of transcription factors to the 5′ upstream enhancer region. In this regard, it was reported that IL-1 and IFNα induce the transcription of <italic>Aicda</italic> through activation of NF-κB in hepatocytes during hepatitis B virus infection (<xref ref-type="bibr" rid="bib60">Watashi et al., 2013</xref>). IL-1 and IFNα have also been reported to activate STAT proteins, if not STAT6 (<xref ref-type="bibr" rid="bib5">Biffi et al., 2019</xref>; <xref ref-type="bibr" rid="bib11">Du et al., 2007</xref>). However, further study would be necessary to understand the overall mechanism for the induction of <italic>Aicda</italic> expression in B cells in the TI-2 response.</p><p>Consistent with our in vitro data, previous reports showed the contribution of IL-1α/β, IFNα, and TLR ligands in several types of TI-2 responses: IgG production upon immunization with NP-Ficoll was dampened in IL-1α/β double-deficient mice (<xref ref-type="bibr" rid="bib36">Nakae et al., 2001</xref>), and IgG2c production with NP-Ficoll plus poly(I:C) was dependent on the IFNα receptor on B cells (<xref ref-type="bibr" rid="bib56">Swanson et al., 2010</xref>). While IgG production against NP-Ficoll did not require MyD88-mediated TLR signaling (<xref ref-type="bibr" rid="bib15">Gavin et al., 2006</xref>; <xref ref-type="bibr" rid="bib18">Hou et al., 2011</xref>), IgG production against pneumococcal polysaccharides requires TLR signaling (<xref ref-type="bibr" rid="bib49">Sen et al., 2005</xref>). Compared to NP-Ficoll, physiological TI-2 Ags are more complex (<xref ref-type="bibr" rid="bib53">Snapper, 2006</xref>) and may contain pathogen-associated molecular patterns (PAMPs) that mediate TLR signaling. Therefore, any of IL-1α/β, IFNα, and TLR ligands could function as costimulation for an in vivo TI-2 response, depending on the type of Ag.</p><p>Our data revealed that PKCδ is generally required for IgG production in response to TI-2 Ags such as NP-Ficoll and PPS3. Given the predominant role of IgG3 in antipneumococcal responses (<xref ref-type="bibr" rid="bib30">McLay et al., 2002</xref>), PKCδ seems to be needed for protection from pneumococcal infection. Furthermore, we found that PKCδ is required to produce IgG3 against commensal bacteria in the steady state and the prevention of bacteremia after epithelial barrier disruption. As commensal bacteria have been shown to contain various Ags and stimulate multiple immune pathways (<xref ref-type="bibr" rid="bib4">Belkaid and Harrison, 2017</xref>), our result suggests that some commensal bacteria express TI-2 Ag-like repetitive structures that elicit IgG3 production. It has been shown that such IgG against symbiotic bacteria also plays a protective role in systemic infection by pathogens (<xref ref-type="bibr" rid="bib63">Zeng et al., 2016</xref>). Taken together, IgG production in the TI-2 response seems to be critical for regulation of various types of bacteria.</p><p>Several reports uncovered the potential contribution of the dysregulated microbiome in SLE pathogenesis together with genetic risk factors (<xref ref-type="bibr" rid="bib51">Silverman, 2019</xref>). Translocation of a gut pathobiont to the liver and other systemic tissues causes a lupus-like disease in genetically autoimmune-prone mice owing to induction of a systemic type I interferon response and autoantibody production (<xref ref-type="bibr" rid="bib29">Manfredo Vieira et al., 2018</xref>). Prevention of this bacterial translocation and autoimmune response by vaccination against the pathobiont indicated a role of antibodies for the prevention. Thus, besides the defect of B-cell tolerance (<xref ref-type="bibr" rid="bib33">Miyamoto et al., 2002</xref>; <xref ref-type="bibr" rid="bib31">Mecklenbräuker et al., 2002</xref>), the low serum antibacterial IgG3 in PKCδ-deficient mice may lead to the pathobiont invasion and autoantibody production through intact TD response. Loss-of-function PKCδ mutations in humans also cause SLE-like autoimmunity (<xref ref-type="bibr" rid="bib48">Salzer et al., 2016</xref>). Some of these patients show reduced IgG-positive B cells in the peripheral blood and have recurrent infections for unknown reasons (<xref ref-type="bibr" rid="bib22">Kiykim et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Salzer et al., 2013</xref>; <xref ref-type="bibr" rid="bib24">Kuehn et al., 2013</xref>). Taken together, PKCδ-mediated IgG production by the TI-2 response appears to be critical also in humans for host defense against certain bacteria and the regulation of autoimmunity.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="middle">Designation</th><th align="left" valign="middle">Source or <break/>reference</th><th align="left" valign="middle">Identifiers</th><th align="left" valign="middle">Additional <break/>information</th></tr></thead><tbody><tr><td align="left" valign="top">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="middle">C57BL/<break/>6NCrSlc (B6)</td><td align="left" valign="middle">Japan SLC Inc</td><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle">C57BL/6 CD45.1</td><td align="left" valign="middle">RIKEN BRC</td><td align="left" valign="middle">RBRC00144</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle"><italic>B1-8<sup>flox/+</sup></italic></td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0092-8674(00)80373-6">10.1016/S0092-8674(00)80373–6</ext-link>.</td><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle"><italic>B1-8<sup>hi</sup></italic></td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni776">10.1038/ni776</ext-link>.</td><td align="left" valign="middle">JAX stock #007775</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle"><italic>Cd19<sup>cre/+</sup></italic></td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/376352a0">10.1038/376352a0</ext-link>.</td><td align="left" valign="middle">JAX stock <break/>#006785</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle"><italic>Prkcd<sup>−/−</sup></italic></td><td align="left" valign="middle">RIKEN BRC</td><td align="left" valign="middle">RBRC00457</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle"><italic>Prkcd<sup>f/f</sup></italic></td><td align="left" valign="middle">RIKEN BRC</td><td align="left" valign="middle">RBRC06462</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="middle"><italic>Igk<sup>−/−</sup></italic></td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/j.1460-2075.1993.tb05722.x">10.1002/j.1460–2075.1993.tb05722.x</ext-link>.</td><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">APC-Cy7 anti-mouse CD19 <break/>(Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 115,530</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Biotin Rat Anti-Mouse CD43 <break/>(Rat monoclonal)</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">Cat# 20,737</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">BV421 anti-mouse CD138 (Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 142,508</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">BV421 Rat Anti-Mouse IgG3 (Rat monoclonal)</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">Cat# 565,808</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">CD45.1 Monoclonal Antibody (A20), APC (Mouse monoclonal)</td><td align="left" valign="middle">Invitrogen</td><td align="left" valign="middle">Cat# 17-0453-82</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">FITC anti-mouse CD21/CD35 (CR2/CR1) Antibody (Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 123,407</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">FITC anti-mouse CD5 Antibody (Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 100,605</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG2c, Human ads-FITC (Goat <break/>Polyclonal)</td><td align="left" valign="middle">Southern<break/>Biotech</td><td align="left" valign="middle">Cat# 1079-02</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat F(ab')2 Anti-Mouse IgG2b, Human ads-FITC <break/>(Goat Polyclonal)</td><td align="left" valign="middle">Southern<break/>Biotech</td><td align="left" valign="middle">Cat# 1092-02</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat F(ab')2 Anti-Mouse IgG3, Human ads-FITC <break/>(Goat Polyclonal)</td><td align="left" valign="middle">Southern<break/>Biotech</td><td align="left" valign="middle">Cat# 1102-02</td><td align="left" valign="middle">Flow <break/>cytometry <break/>(1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">PE anti-mouse CD23 Antibody (Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 101,607</td><td align="left" valign="middle">Flow <break/>cytometry (1/300)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">PE anti-mouse IgG2b (Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 406,707</td><td align="left" valign="middle">Flow <break/>cytometry (1/500)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">PE-Cy7 anti-mouse CD19 (Rat monoclonal)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">Cat# 115,520</td><td align="left" valign="middle">Flow cytometry (1/200)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG Fc-HRP (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1033-05</td><td align="left" valign="middle">ELISA (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG, Human ads-UNLB (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1030-01</td><td align="left" valign="middle">ELISA (1/1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG1, Human ads-HRP (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1070-05</td><td align="left" valign="middle">ELISA (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG1, Human ads-UNLB (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1070-01</td><td align="left" valign="middle">ELISA (1/1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG2b, Human ads-HRP (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1090-05</td><td align="left" valign="middle">ELISA (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG2b, Human ads-UNLB (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1090-01</td><td align="left" valign="middle">ELISA (1/1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG2c, Human ads-HRP (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1079-05</td><td align="left" valign="middle">ELISA (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG3, Human ads-UNLB (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1100-01</td><td align="left" valign="middle">ELISA (1/1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgG3, Human/Bovine/Horse SP ads-HRP (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1103-05</td><td align="left" valign="middle">ELISA (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgM, Human ads-HRP (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1020-05</td><td align="left" valign="middle">ELISA (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Goat Anti-Mouse IgM, Human ads-UNLB (Goat Polyclonal)</td><td align="left" valign="middle">SouthernBiotech</td><td align="left" valign="middle">Cat# 1020-01</td><td align="left" valign="middle">ELISA (1/1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Anti-GAPDH mAb (Mouse monoclonal)</td><td align="left" valign="middle">MBL</td><td align="left" valign="middle">Cat# M171-3</td><td align="left" valign="middle">WB (1/3000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Anti-SP1 antibody (Rabbit polyclonal)</td><td align="left" valign="middle">Abcam</td><td align="left" valign="middle">Cat# ab227383</td><td align="left" valign="middle">WB (1/5000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">BATF (D7C5) Rabbit mAb (Rabbit monoclonal)</td><td align="left" valign="middle">Cell Signaling <break/>Technology</td><td align="left" valign="middle">Cat# 8638</td><td align="left" valign="middle">WB (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">Phospho-PKCdelta (Tyr311) Antibody (Rabbit polyclonal)</td><td align="left" valign="middle">Cell Signaling <break/>Technology</td><td align="left" valign="middle">Cat# 2055</td><td align="left" valign="middle">WB (1/2000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="middle">PKC δ Antibody (C-17) (Rabbit polyclonal)</td><td align="left" valign="middle">Santa Cruz <break/>Biotechnology</td><td align="left" valign="middle">Cat# sc-213</td><td align="left" valign="middle">WB (1/2000)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pMXs-IRES-GFP</td><td align="left" valign="middle">other</td><td align="left" valign="middle"/><td align="left" valign="middle">Dr. Kitamura (University of Tokyo)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pMXs-BATF-IRES-GFP</td><td align="left" valign="middle">This paper</td><td align="left" valign="middle"/><td align="left" valign="middle">BATF (<italic>M. musculus</italic>)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pMXs-AID-IRES-GFP</td><td align="left" valign="middle">This paper</td><td align="left" valign="middle"/><td align="left" valign="middle">AID (<italic>M. musculus</italic>)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pMXs-PKCδ-IRES-GFP</td><td align="left" valign="middle">This paper</td><td align="left" valign="middle"/><td align="left" valign="middle">PKCδ (<italic>M. musculus</italic>)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pSIREN-GFP shLuciferase (shControl)</td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2020.108333">10.1016/j.celrep.2020.108333</ext-link>.</td><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pSIREN-GFP shBATF</td><td align="left" valign="middle">This paper</td><td align="left" valign="middle"/><td align="left" valign="middle">Taget sequence <break/>(5′–3′): ACCCTGGAC<break/>TGTCATGAATGA</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="middle">pVSV-G</td><td align="left" valign="middle">Clontech</td><td align="left" valign="middle">Cat# 631,530</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="middle">Primers</td><td align="left" valign="middle">This paper</td><td align="left" valign="middle"/><td align="left" valign="middle">See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr><tr><td align="left" valign="top">Sequence-based reagent</td><td align="left" valign="middle">Oligo(dT)<break/>20 Primer</td><td align="left" valign="middle">Thermo <break/>Fisher <break/>Scientific</td><td align="left" valign="middle">Cat# 18418020</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="middle">NP46-Ficoll</td><td align="left" valign="middle">Biosearch <break/>Technologies</td><td align="left" valign="middle">Cat# F-1420</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="middle">NP40-CGG</td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.3508">10.1038/ni.3508</ext-link>.</td><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="middle">NP14-BSA-<break/>Alexa Fluor 647</td><td align="left" valign="middle">doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.3508">10.1038/ni.3508</ext-link>.</td><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="middle">Cytokines</td><td align="center" colspan="2" valign="middle">See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="middle">Fixation/<break/>Permeabilization <break/>Solution Kit</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">Cat# 554,714</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="middle">QIAquick PCR Purification Kit</td><td align="left" valign="middle">QIAGEN</td><td align="left" valign="middle">Cat# 28,106</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="middle">RNeasy Micro</td><td align="left" valign="middle">QIAGEN</td><td align="left" valign="middle">Cat# 74,004</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="middle">Thunderbird SYBR qPCR Mix</td><td align="left" valign="middle">TOYOBO</td><td align="left" valign="middle">Cat# QPS-201</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="middle">SuperPrep II <break/>Cell lysis &amp; RT <break/>Kit for qPCR</td><td align="left" valign="middle">TOYOBO</td><td align="left" valign="middle">Cat# SCQ-401</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="middle">CellTraceTM <break/>Violet (CTV) <break/>Cell <break/>proliferation Kit</td><td align="left" valign="middle">Thermo <break/>Fisher <break/>Scientific</td><td align="left" valign="middle">Cat# C34557</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">PPS3</td><td align="left" valign="middle">ATCC</td><td align="left" valign="middle">Cat# 169X</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">LPS</td><td align="left" valign="middle">Sigma</td><td align="left" valign="middle">Cat# L2880</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">R-848</td><td align="left" valign="middle">InvivoGen</td><td align="left" valign="middle">Cat# tlrl-r848</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">CpG ODN 1826</td><td align="left" valign="middle">InvivoGen</td><td align="left" valign="middle">Cat# tlrl-1826</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">Fixable Viability Dye eFluor 506</td><td align="left" valign="middle">Thermo <break/>Fisher <break/>Scientific</td><td align="left" valign="middle">Cat# 65-0866-18</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">DOTAP Liposomal Transfection Reagent</td><td align="left" valign="middle">Sigma</td><td align="left" valign="middle">Cat# 11202375001</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">TRI Reagent</td><td align="left" valign="middle">Sigma</td><td align="left" valign="middle">Cat# T9424</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">PEI Max (Mw 40,000)</td><td align="left" valign="middle">Polysciences</td><td align="left" valign="middle">Cat# 24765-1</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">ReverTra Ace</td><td align="left" valign="middle">TOYOBO</td><td align="left" valign="middle">Cat# TRT-101</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">KOD Fx Neo DNA polymerase</td><td align="left" valign="middle">TOYOBO</td><td align="left" valign="middle">Cat# KFX-201</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">[<sup>3</sup> H] thymidine</td><td align="left" valign="middle">PerkinElmer</td><td align="left" valign="middle">Cat# NET027001MC</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">anti-APC MicroBeads</td><td align="left" valign="middle">MicroBeads</td><td align="left" valign="middle">Cat# 130-090-855</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">GoTaq Green Master Mix</td><td align="left" valign="middle">Promega</td><td align="left" valign="middle">Cat# M712B</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">DSS</td><td align="left" valign="middle">MP Biomedicals</td><td align="left" valign="middle">Cat# 9011-18-1</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="middle">Brain Heart Infusion Agar</td><td align="left" valign="middle">BD Bioscience</td><td align="left" valign="middle">Cat# 221,570</td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="middle">FlowJo</td><td align="left" valign="middle"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td><td align="left" valign="middle">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="middle"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="middle">GraphPad Prism</td><td align="left" valign="middle"><ext-link ext-link-type="uri" xlink:href="https://graphpad.com">https://graphpad.com</ext-link></td><td align="left" valign="middle">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="middle"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice and immunizations</title><p>C57BL/6NCrSlc (B6) mice were purchased from Japan SLC. All the following mice were backcrossed to the B6 or B6-CD45.1 strain: <italic>B1-8<sup>flox/+</sup></italic> mice (<xref ref-type="bibr" rid="bib25">Lam et al., 1997</xref>), <italic>B1-8<sup>hi</sup></italic> mice (<xref ref-type="bibr" rid="bib50">Shih et al., 2002</xref>), <italic>Igk<sup>–/–</sup></italic> mice (<xref ref-type="bibr" rid="bib7">Chen et al., 1993</xref>), <italic>Cd19<sup>cre/+</sup></italic> mice (<xref ref-type="bibr" rid="bib44">Rickert et al., 1995</xref>), and <italic>Prkcd<sup>–/–</sup></italic> mice (<xref ref-type="bibr" rid="bib33">Miyamoto et al., 2002</xref>). <italic>Prkcd <sup>fl/fl</sup></italic> mice on the B6 background were developed by Drs. Niino, Shioda, and Sakimura (<xref ref-type="bibr" rid="bib38">Niino et al., 2021</xref>) and purchased from the RIKEN BioResource Center (RBRC06462). Mice were immunized i.p. with 100 µg of NP<sub>46</sub>-Ficoll (F-1420; Biosearch Technologies), 1 µg of PPS3 (169 X; American Type Culture Collection) or 100 µg of NP<sub>40</sub>-CGG in alum (<xref ref-type="bibr" rid="bib16">Haniuda et al., 2016</xref>) unless otherwise noted. For flow cytometry of spleen cells, mice were immunized i.v. with 100 µg of NP<sub>46</sub>-Ficoll. Sex-matched 7–14-week-old mice were used for all experiments. All mice were maintained in the Tokyo University of Science (TUS) mouse facility under specific pathogen-free conditions. Mouse procedures were performed under protocols approved by the TUS Animal Care and Use Committee (Approval No. S19017 and S20011).</p></sec><sec id="s4-2"><title>B-cell culture</title><p>Spleen cells were stained with a cocktail of biotinylated Abs for CD4, CD8, CD43, CD49b, Ter119, and Streptavidin Particles Plus DM, from which naive B cells were purified by magnetic negative sorting using the IMag system (BD Biosciences) and MACS system (Miltenyi Biotec), as described previously (<xref ref-type="bibr" rid="bib40">Nojima et al., 2011</xref>). B cells were cultured in RPMI-1640 medium (Wako) supplemented with 10% heat-inactivated fetal bovine serum, 10 mM HEPES pH 7.5, 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO). Typically, B cells were cultured at 2 × 10<sup>5</sup> /ml in the presence of the following stimuli at the indicated doses, unless otherwise noted: NP<sub>46</sub>-Ficoll (10 ng/ml), NP<sub>40</sub>-CGG (10 ng/ml), LPS (1 µg/ml, L2880; Sigma), R-848 (1 µg/ml, tlrl-r848; InvivoGen), CpG ODN 1826 (1 µg/ml, tlrl-1826; InvivoGen), IL-1α (1 ng/ml, 211–11 A; Pepro Tech), IL-1β (1 ng/ml, 211-11B; Pepro Tech), or IFNα (100 ng/ml, 752802; Biolegend). Concentrations of cytokines used in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref> are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-3"><title>Retroviral transduction</title><p>To produce retrovirus, pSIREN- or pMXs-based plasmids were cotransfected together with pVSVG into Plat-E cells (kindly provided by T. Kitamura, University of Tokyo) using PEI Max (Mw 40,000, 24765-1; Polysciences). The virus-containing supernatant was harvested 2 days after transfection. For retroviral transduction, B cells were preactivated in vivo: <italic>B1-8</italic><sup><italic>hi</italic></sup> mice were injected i.p. with 50 µg of NP-Ficoll, and then B cells were purified from the spleens of these mice on the next day. These B cells were mixed with the virus-containing supernatant and spin infected at 2000 rpm, 37°C for 90 min with 10 mg/ml DOTAP Liposomal Transfection Reagent (11202375001; Sigma). One day later, the cells were harvested and 5 × 10<sup>5</sup> cells were transferred into B6 mice that had been immunized i.v. with NP-Ficoll on the previous day. This strategy is summarized in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</p></sec><sec id="s4-4"><title>Proliferation assay</title><p>The proliferation assay was performed as described previously (<xref ref-type="bibr" rid="bib14">Fukao et al., 2014</xref>). Naive B cells were cultured at 5 × 10<sup>4</sup> cells/well in 96-well plates for 72 hr, with the last 8 hr in the presence of [<sup>3</sup>H] thymidine (1 mCi/well, NET027001MC; PerkinElmer). Incorporated [<sup>3</sup>H] thymidine was counted by a BetaPlate scintillation counter (Wallac, Gaithersburg, MD).</p></sec><sec id="s4-5"><title>Flow cytometry</title><p>Single-cell suspensions from spleen or peritoneal cavity were prepared, red blood cells were lysed with ammonium chloride buffer and then cells were incubated with anti-CD16/32 Ab (2.4G2) to block FcγRs. Cultured B cells were collected in MACS buffer (phosphate-buffered saline [PBS] supplemented with 0.5 % BSA, 2 mM ethylenediaminetetraacetic acid [EDTA]) at the indicated days of culture. Cells were stained with Abs and reagents on ice (for splenocytes) or at room temperature (for cultured B cells). For the staining of IgM, IgG, and NP-binding Ig, Fixation/Permeabilization Solution Kit (554714; BD Biosciences) was used according to the manufacturer’s protocol to detect total (surface and intracellular) proteins, after surface staining of other molecules. NP-binding Ig was stained with NP<sub>14</sub>-BSA-Alexa Fluor 647 (<xref ref-type="bibr" rid="bib16">Haniuda et al., 2016</xref>). Dead cells were stained with Fixable Viability dye eFluor 506 (65-0866-18; Thermo Fisher Scientific) before cell fixation and excluded from analysis. All samples were analyzed using FACSCanto II, FACSAria II or III (BD Biosciences) with FlowJo software (Tree Star, Inc).</p></sec><sec id="s4-6"><title>Cell division analysis</title><p>Naïve B cells were resuspended in PBS at 5 × 10<sup>6</sup> cells/ml and labeled with 5 µM of CTV Cell proliferation Kit (C34557; Thermo Fisher Scientific) at 37 °C for 20 min according to the manufacturer’s protocol. Collected cells were analyzed by flow cytometry as described above. Cell divisions were determined using the proliferation platform of FlowJo.</p></sec><sec id="s4-7"><title>Adaptive transfer and donor B-cell purification</title><p>1 × 10<sup>6</sup> CD45.1 <italic>B1-8<sup>hi</sup></italic> naive B cells were transferred into B6 mice, which were then immunized i.v. with NP-Ficoll on the next day. Donor B cells were magnetically enriched from pooled spleens of recipient mice using APC-conjugated anti-CD45.1 and anti-APC MicroBeads (130-090-855; Miltenyi Biotec), with the MACS system (Miltenyi Biotec). After enrichment, cells were further stained with respective Abs and sorted using FACSAria II or III (BD Biosciences) as shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. Rv-transduced donor B cells were enriched as described above and sorted as shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>.</p></sec><sec id="s4-8"><title>RT-PCR and qPCR</title><p>TRI Reagent (T9424; Sigma) or RNeasy Micro (74004; QIAGEN) was used to isolate total RNA from B cells. cDNA was generated from total RNA using ReverTra Ace (TRT-101; TOYOBO) with an oligo(dT)20 primer (18418020; Thermo Fisher Scientific) according to the manufacturer’s protocols. For the analysis of a small number of cells, cDNA was generated from cell lysates with SuperPrep II Cell lysis &amp; RT Kit for qPCR (SCQ-401; TOYOBO) according to the manufacturer’s protocols. Quantitative real-time PCR (qPCR) was performed using Thunderbird SYBR qPCR Mix (QPS-201; TOYOBO) with the 7500 fast Real-time PCR system or Quant-Studio 3 (Applied Biosystems). For quantification of gene expression levels, each sample was normalized to the expression of a control housekeeping gene, <italic>Gapdh</italic> or <italic>Rps18</italic>. The relative fold change in expression of each gene compared to a control sample, set as 1.0, was calculated with the 2-ddCT method. Primers used in this study are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The germline and postswitched transcripts were analyzed with the following primer sets: germline Iµ-Cµ transcripts: Iµ Fw1 and Cµ Rv; Iγ3-Cγ3 transcripts: inner Iγ3 Fw and Cγ3 Rv; postswitched Iµ-Cγ3 transcripts: Iµ Fw2 and Cγ3 Rv. For the measurement of the circle Iγ3-Cµ transcript, cDNA was generated with external Cµ Rv primer from total RNA as described above, and preamplified with external Iγ3 Fw primer and Cµ Rv primer using GoTaq Green Master Mix (M712B; Promega). Preapplication products were purified with QIAquick PCR Purification Kit (28104; QIAGEN) and circle Iγ3-Cµ transcript was quantified with inner Iγ3 Fw primer and Cµ Rv primer by qPCR as described above. Specific amplification of the circle Iγ3-Cµ transcript was confirmed by analyzing the sequence of the qPCR products in advance. The expression of the Iγ3-Cµ transcript was normalized to the expression of Rps18 in cDNA generated with oligo(dT)20 primer from the same RNA sample.</p></sec><sec id="s4-9"><title>Enzyme-linked immunosorbent assay</title><p>Concentrations of total IgM, IgG, or IgG subclasses and of Ag-specific Igs (where indicated) were assessed by titration of culture supernatants or sera by enzyme-linked immunosorbent assay (ELISA). Total and NP-specific antibodies were measured as described previously (<xref ref-type="bibr" rid="bib14">Fukao et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Nojima et al., 2011</xref>), with NP<sub>13.6</sub>-BSA used for coating plates for the latter. PPS3-specific IgM and IgG3 were detected using 96-well plates coated with PPS3. Bacteria-specific antibody was detected as described previously (<xref ref-type="bibr" rid="bib63">Zeng et al., 2016</xref>). Heat-killed fecal bacteria isolated from <italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup></italic>mice and <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup></italic>mice cohoused at least for 4 weeks were mixed and used for plate coating.</p></sec><sec id="s4-10"><title>Immunoblotting</title><p>Cells were lysed with 1% NP-40 lysis buffer or RIPA buffer (40 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1 % sodium deoxycholate, 0.1 % SDS, and 1 mM EDTA) supplemented with protease and phosphatase inhibitors. Lysates were sonicated and mixed with sample buffer and dithiothreitol and boiled. Lysates were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore), followed by immunoblotting as previously described (<xref ref-type="bibr" rid="bib17">Haniuda et al., 2020</xref>).</p></sec><sec id="s4-11"><title>DSS-induced bacteremia</title><p><italic>Prkcd<sup>+/+</sup> Cd19<sup>cre/+</sup></italic>mice and <italic>Prkcd<sup>f/f</sup> Cd19<sup>cre/+</sup></italic> female mice were cohoused at 1:1 ratio from 4 weeks of age. After at least 4 weeks, cohoused mice were administered 3 % DSS (9011-18-1; MP Biomedicals) in drinking water for 7 days and then switched to regular water. On the day of the last DSS administration, blood samples were collected from mice and cultured on Brain Heart Infusion Agar (221570; BD Bioscience) under aerobic or anaerobic conditions for 24 hr to measure CFU.</p></sec><sec id="s4-12"><title>Statistical analysis</title><p>Biological replication is derived from multiple biological samples (mouse or cell). Technical replication consisted of multiple samples derived from one biological sample. All statistical analyses were performed using GraphPad Prism eight software. Comparisons between two groups were performed by a two-tailed unpaired Student’s <italic>t</italic>-test, Welch’s <italic>t</italic>-test (in case <italic>F</italic>-test is significant: p &lt; 0.05), or multiple <italic>t</italic>-test (for grouped data). Comparisons between multiple groups were performed by one or two-way analysis of variance with Tukey’s multiple comparison. Survival of DSS-treated mice was analyzed by Kaplan–Meier survival plot using log-rank test. In all cases, *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001; ****p &lt; 0.0001; ns, not significant (p &gt; 0.05).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Validation, Visualization, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Supervision, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All mice were maintained in the Tokyo University of Science (TUS) mouse facility under specific pathogen-free conditions. Mouse procedures were performed under protocols approved by the TUS Animal Care and Use Committee (Approval No.: S19017, S20011).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>The list of cytokines and primers used in this study.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72116-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-72116-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1-6, and figure supplements for Figures 1-3 and 5.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Drs S Shioda, Y Niino, T Nakamachi, and J Watanabe (Showa University) for <italic>Prkcd <sup>fl/fl</sup></italic> mice; K Nakayama (Kyushu University) for <italic>Prkcd<sup>–/–</sup></italic> mice; K Rajewsky (Max Delbrück Center for Molecular Medicine) for <italic>B1-8<sup>flox/+</sup></italic> mice and <italic>Cd19<sup>cre/+</sup></italic> mice; M Nussenzweig (Rockefeller University) for <italic>B1-8<sup>hi</sup></italic> mice; F Alt (Harvard Medical School) and T Tsubata (Tokyo Medical and Dental University) for <italic>Igk<sup>–/–</sup></italic> mice; and P Burrows for critical reading of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansaldo</surname><given-names>E</given-names></name><name><surname>Slayden</surname><given-names>LC</given-names></name><name><surname>Ching</surname><given-names>KL</given-names></name><name><surname>Koch</surname><given-names>MA</given-names></name><name><surname>Wolf</surname><given-names>NK</given-names></name><name><surname>Plichta</surname><given-names>DR</given-names></name><name><surname>Brown</surname><given-names>EM</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Moon</surname><given-names>JJ</given-names></name><name><surname>Barton</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis</article-title><source>Science</source><volume>364</volume><fpage>1179</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1126/science.aaw7479</pub-id><pub-id pub-id-type="pmid">31221858</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Eckert</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Apigenin inhibition of involucrin gene expression is associated with a specific reduction in phosphorylation of protein kinase Cdelta Tyr311</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>36162</fpage><lpage>36172</lpage><pub-id pub-id-type="doi">10.1074/jbc.M605368200</pub-id><pub-id pub-id-type="pmid">16982614</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balázs</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Kearney</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Blood dendritic cells interact with splenic marginal zone B cells to Initiate T-independent immune responses</article-title><source>Immunity</source><volume>17</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00389-8</pub-id><pub-id pub-id-type="pmid">12354386</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belkaid</surname><given-names>Y</given-names></name><name><surname>Harrison</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Homeostatic immunity and the microbiota</article-title><source>Immunity</source><volume>46</volume><fpage>562</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.04.008</pub-id><pub-id pub-id-type="pmid">28423337</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Oni</surname><given-names>TE</given-names></name><name><surname>Spielman</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Preall</surname><given-names>J</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>282</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0710</pub-id><pub-id pub-id-type="pmid">30366930</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castigli</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><name><surname>Dedeoglu</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>KP</given-names></name><name><surname>Bram</surname><given-names>RJ</given-names></name><name><surname>Jabara</surname><given-names>H</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>TACI and BAFF-R mediate isotype switching in B cells</article-title><source>The Journal of Experimental Medicine</source><volume>201</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1084/jem.20032000</pub-id><pub-id pub-id-type="pmid">15630136</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Trounstine</surname><given-names>M</given-names></name><name><surname>Kurahara</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>F</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Loring</surname><given-names>JF</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Huszar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>B cell development in mice that lack one or both immunoglobulin kappa light chain genes</article-title><source>The EMBO Journal</source><volume>12</volume><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1993.tb05722.x</pub-id><pub-id pub-id-type="pmid">8458340</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crouch</surname><given-names>EE</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Takizawa</surname><given-names>M</given-names></name><name><surname>Fichtner-Feigl</surname><given-names>S</given-names></name><name><surname>Gourzi</surname><given-names>P</given-names></name><name><surname>Montaño</surname><given-names>C</given-names></name><name><surname>Feigenbaum</surname><given-names>L</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Janz</surname><given-names>S</given-names></name><name><surname>Papavasiliou</surname><given-names>FN</given-names></name><name><surname>Casellas</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Regulation of AID expression in the immune response</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>1145</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1084/jem.20061952</pub-id><pub-id pub-id-type="pmid">17452520</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dedeoglu</surname><given-names>F</given-names></name><name><surname>Horwitz</surname><given-names>B</given-names></name><name><surname>Chaudhuri</surname><given-names>J</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB</article-title><source>Ternational Immunology</source><volume>16</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh042</pub-id><pub-id pub-id-type="pmid">14978013</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deenick</surname><given-names>EK</given-names></name><name><surname>Hasbold</surname><given-names>J</given-names></name><name><surname>Hodgkin</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Switching to IgG3, IgG2b, and IgA is division linked and independent, revealing a stochastic framework for describing differentiation</article-title><source>Journal of Immunology</source><volume>163</volume><fpage>4707</fpage><lpage>4714</lpage><pub-id pub-id-type="pmid">10528168</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Murti</surname><given-names>A</given-names></name><name><surname>Pfeffer</surname><given-names>SR</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Pfeffer</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway</article-title><source>Journal of Cellular Biochemistry</source><volume>102</volume><fpage>1087</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1002/jcb.21535</pub-id><pub-id pub-id-type="pmid">17910035</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellmeier</surname><given-names>W</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Sunshine</surname><given-names>MJ</given-names></name><name><surname>Hatam</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Mano</surname><given-names>H</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Severe B cell deficiency in mice lacking the Tec kinase family members Tec and Btk</article-title><source>The Journal of Experimental Medicine</source><volume>192</volume><fpage>1611</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1084/jem.192.11.1611</pub-id><pub-id pub-id-type="pmid">11104803</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruman</surname><given-names>DA</given-names></name><name><surname>Satterthwaite</surname><given-names>AB</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Xid-like phenotypes: a B cell signalosome takes shape</article-title><source>Immunity</source><volume>13</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)00002-9</pub-id><pub-id pub-id-type="pmid">10933389</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukao</surname><given-names>S</given-names></name><name><surname>Haniuda</surname><given-names>K</given-names></name><name><surname>Nojima</surname><given-names>T</given-names></name><name><surname>Takai</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>gp49B-mediated negative regulation of antibody production by memory and marginal zone B cells</article-title><source>Journal of Immunology</source><volume>193</volume><fpage>635</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302772</pub-id><pub-id pub-id-type="pmid">24935931</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>AL</given-names></name><name><surname>Hoebe</surname><given-names>K</given-names></name><name><surname>Duong</surname><given-names>B</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling</article-title><source>Science</source><volume>314</volume><fpage>1936</fpage><lpage>1938</lpage><pub-id pub-id-type="doi">10.1126/science.1135299</pub-id><pub-id pub-id-type="pmid">17185603</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haniuda</surname><given-names>K</given-names></name><name><surname>Fukao</surname><given-names>S</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autonomous membrane IgE signaling prevents IgE-memory formation</article-title><source>Nature Immunology</source><volume>17</volume><fpage>1109</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1038/ni.3508</pub-id><pub-id pub-id-type="pmid">27428827</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haniuda</surname><given-names>K</given-names></name><name><surname>Fukao</surname><given-names>S</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metabolic reprogramming induces germinal center B cell differentiation through Bcl6 locus remodeling</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108333</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108333</pub-id><pub-id pub-id-type="pmid">33147467</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>B</given-names></name><name><surname>Saudan</surname><given-names>P</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Wheeler</surname><given-names>ML</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name><name><surname>Kuzmich</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>LM</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>Bachmann</surname><given-names>MF</given-names></name><name><surname>DeFranco</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Selective utilization of toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response</article-title><source>Immunity</source><volume>34</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.01.011</pub-id><pub-id pub-id-type="pmid">21353603</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ise</surname><given-names>W</given-names></name><name><surname>Kohyama</surname><given-names>M</given-names></name><name><surname>Schraml</surname><given-names>BU</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Schwer</surname><given-names>B</given-names></name><name><surname>Basu</surname><given-names>U</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Oltz</surname><given-names>EM</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells</article-title><source>Nature Immunology</source><volume>12</volume><fpage>536</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/ni.2037</pub-id><pub-id pub-id-type="pmid">21572431</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>WN</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Gerstein</surname><given-names>RM</given-names></name><name><surname>Malynn</surname><given-names>BA</given-names></name><name><surname>Larsson</surname><given-names>I</given-names></name><name><surname>Rathbun</surname><given-names>G</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Müller</surname><given-names>S</given-names></name><name><surname>Kantor</surname><given-names>AB</given-names></name><name><surname>Herzenberg</surname><given-names>LA</given-names></name><name><surname>Rosen</surname><given-names>FS</given-names></name><name><surname>Sideras</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Defective B cell development and function in Btk-deficient mice</article-title><source>Immunity</source><volume>3</volume><fpage>283</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/1074-7613(95)90114-0</pub-id><pub-id pub-id-type="pmid">7552994</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Harigai</surname><given-names>M</given-names></name><name><surname>Fagarasan</surname><given-names>S</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A hallmark of active class switch recombination: Transcripts directed by I promoters on looped-out circular DNAs</article-title><source>PNAS</source><volume>98</volume><fpage>12620</fpage><lpage>12623</lpage><pub-id pub-id-type="doi">10.1073/pnas.221454398</pub-id><pub-id pub-id-type="pmid">11606740</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiykim</surname><given-names>A</given-names></name><name><surname>Ogulur</surname><given-names>I</given-names></name><name><surname>Baris</surname><given-names>S</given-names></name><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Karakoc-Aydiner</surname><given-names>E</given-names></name><name><surname>Ozen</surname><given-names>AO</given-names></name><name><surname>Garncarz</surname><given-names>W</given-names></name><name><surname>Hirschmugl</surname><given-names>T</given-names></name><name><surname>Krolo</surname><given-names>A</given-names></name><name><surname>Yucelten</surname><given-names>AD</given-names></name><name><surname>Boztug</surname><given-names>K</given-names></name><name><surname>Barlan</surname><given-names>IB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Potentially beneficial effect of hydroxychloroquine in a patient with a novel mutation in protein kinase Cδ deficiency</article-title><source>Journal of Clinical Immunology</source><volume>35</volume><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1007/s10875-015-0178-9</pub-id><pub-id pub-id-type="pmid">26233237</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>MA</given-names></name><name><surname>Reiner</surname><given-names>GL</given-names></name><name><surname>Lugo</surname><given-names>KA</given-names></name><name><surname>Kreuk</surname><given-names>LSM</given-names></name><name><surname>Stanbery</surname><given-names>AG</given-names></name><name><surname>Ansaldo</surname><given-names>E</given-names></name><name><surname>Seher</surname><given-names>TD</given-names></name><name><surname>Ludington</surname><given-names>WB</given-names></name><name><surname>Barton</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Maternal IgG and IgA antibodies dampen mucosal T helper cell responses in early life</article-title><source>Cell</source><volume>165</volume><fpage>827</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.055</pub-id><pub-id pub-id-type="pmid">27153495</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Niemela</surname><given-names>JE</given-names></name><name><surname>Rangel-Santos</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Stoddard</surname><given-names>JL</given-names></name><name><surname>Hussey</surname><given-names>AA</given-names></name><name><surname>Evbuomwan</surname><given-names>MO</given-names></name><name><surname>Priel</surname><given-names>DAL</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Park</surname><given-names>CL</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name><name><surname>Oliveira</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans</article-title><source>Blood</source><volume>121</volume><fpage>3117</fpage><lpage>3125</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-469544</pub-id><pub-id pub-id-type="pmid">23430113</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>KP</given-names></name><name><surname>Kühn</surname><given-names>R</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death</article-title><source>Cell</source><volume>90</volume><fpage>1073</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80373-6</pub-id><pub-id pub-id-type="pmid">9323135</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesinski</surname><given-names>GB</given-names></name><name><surname>Westerink</surname><given-names>MAJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Vaccines against polysaccharide antigens</article-title><source>Current Drug Targets. Infectious Disorders</source><volume>1</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.2174/1568005014605964</pub-id><pub-id pub-id-type="pmid">12455405</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limnander</surname><given-names>A</given-names></name><name><surname>Depeille</surname><given-names>P</given-names></name><name><surname>Freedman</surname><given-names>TS</given-names></name><name><surname>Liou</surname><given-names>J</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Roose</surname><given-names>JP</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>STIM1, PKC-δ and RasGRP set a threshold for proapoptotic Erk signaling during B cell development</article-title><source>Nature Immunology</source><volume>12</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1038/ni.2016</pub-id><pub-id pub-id-type="pmid">21441934</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magri</surname><given-names>G</given-names></name><name><surname>Miyajima</surname><given-names>M</given-names></name><name><surname>Bascones</surname><given-names>S</given-names></name><name><surname>Mortha</surname><given-names>A</given-names></name><name><surname>Puga</surname><given-names>I</given-names></name><name><surname>Cassis</surname><given-names>L</given-names></name><name><surname>Barra</surname><given-names>CM</given-names></name><name><surname>Comerma</surname><given-names>L</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Gentile</surname><given-names>M</given-names></name><name><surname>Llige</surname><given-names>D</given-names></name><name><surname>Cols</surname><given-names>M</given-names></name><name><surname>Serrano</surname><given-names>S</given-names></name><name><surname>Aróstegui</surname><given-names>JI</given-names></name><name><surname>Juan</surname><given-names>M</given-names></name><name><surname>Yagüe</surname><given-names>J</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Fagarasan</surname><given-names>S</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells</article-title><source>Nature Immunology</source><volume>15</volume><fpage>354</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/ni.2830</pub-id><pub-id pub-id-type="pmid">24562309</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manfredo Vieira</surname><given-names>S</given-names></name><name><surname>Hiltensperger</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Zegarra-Ruiz</surname><given-names>D</given-names></name><name><surname>Dehner</surname><given-names>C</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Costa</surname><given-names>FRC</given-names></name><name><surname>Tiniakou</surname><given-names>E</given-names></name><name><surname>Greiling</surname><given-names>T</given-names></name><name><surname>Ruff</surname><given-names>W</given-names></name><name><surname>Barbieri</surname><given-names>A</given-names></name><name><surname>Kriegel</surname><given-names>C</given-names></name><name><surname>Mehta</surname><given-names>SS</given-names></name><name><surname>Knight</surname><given-names>JR</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Goodman</surname><given-names>AL</given-names></name><name><surname>Kriegel</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Translocation of a gut pathobiont drives autoimmunity in mice and humans</article-title><source>Science</source><volume>359</volume><fpage>1156</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1126/science.aar7201</pub-id><pub-id pub-id-type="pmid">29590047</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLay</surname><given-names>J</given-names></name><name><surname>Leonard</surname><given-names>E</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Shapiro</surname><given-names>D</given-names></name><name><surname>Greenspan</surname><given-names>NS</given-names></name><name><surname>Schreiber</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1</article-title><source>Journal of Immunology</source><volume>168</volume><fpage>3437</fpage><lpage>3443</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.7.3437</pub-id><pub-id pub-id-type="pmid">11907102</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecklenbräuker</surname><given-names>I</given-names></name><name><surname>Saijo</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Protein kinase Cdelta controls self-antigen-induced B-cell tolerance</article-title><source>Nature</source><volume>416</volume><fpage>860</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1038/416860a</pub-id><pub-id pub-id-type="pmid">11976686</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecklenbräuker</surname><given-names>I</given-names></name><name><surname>Kalled</surname><given-names>SL</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling</article-title><source>Nature</source><volume>431</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1038/nature02955</pub-id><pub-id pub-id-type="pmid">15361883</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>A</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Imaki</surname><given-names>H</given-names></name><name><surname>Hirose</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Tsukiyama</surname><given-names>T</given-names></name><name><surname>Nagahama</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Hatakeyama</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta</article-title><source>Nature</source><volume>416</volume><fpage>865</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1038/416865a</pub-id><pub-id pub-id-type="pmid">11976687</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mond</surname><given-names>JJ</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Snapper</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>T cell-independent antigens type 2</article-title><source>Annual Review of Immunology</source><volume>13</volume><fpage>655</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.13.040195.003255</pub-id><pub-id pub-id-type="pmid">7612238</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Fagarasan</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Shinkai</surname><given-names>Y</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme</article-title><source>Cell</source><volume>102</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)00078-7</pub-id><pub-id pub-id-type="pmid">11007474</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakae</surname><given-names>S</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Horai</surname><given-names>R</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Interleukin-1 beta, but not interleukin-1 alpha, is required for T-cell-dependent antibody production</article-title><source>Immunology</source><volume>104</volume><fpage>402</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.2001.01337.x</pub-id><pub-id pub-id-type="pmid">11899425</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>H</given-names></name><name><surname>Frank</surname><given-names>GD</given-names></name><name><surname>Shirai</surname><given-names>H</given-names></name><name><surname>Hinoki</surname><given-names>A</given-names></name><name><surname>Higuchi</surname><given-names>S</given-names></name><name><surname>Ohtsu</surname><given-names>H</given-names></name><name><surname>Eguchi</surname><given-names>K</given-names></name><name><surname>Sanjay</surname><given-names>A</given-names></name><name><surname>Reyland</surname><given-names>ME</given-names></name><name><surname>Dempsey</surname><given-names>PJ</given-names></name><name><surname>Inagami</surname><given-names>T</given-names></name><name><surname>Eguchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Novel role of protein kinase C-delta Tyr 311 phosphorylation in vascular smooth muscle cell hypertrophy by angiotensin II</article-title><source>Hypertension</source><volume>51</volume><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.101253</pub-id><pub-id pub-id-type="pmid">18180404</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niino</surname><given-names>YS</given-names></name><name><surname>Kawashima</surname><given-names>I</given-names></name><name><surname>Iguchi</surname><given-names>Y</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Ogura</surname><given-names>K</given-names></name><name><surname>Mita-Yoshida</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Sakimura</surname><given-names>K</given-names></name><name><surname>Yogosawa</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Shioda</surname><given-names>S</given-names></name><name><surname>Gotoh</surname><given-names>T</given-names></name><name><surname>Fraidenraich</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0253912</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0253912</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niiro</surname><given-names>H</given-names></name><name><surname>Clark</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regulation of B-cell fate by antigen-receptor signals</article-title><source>Nature Reviews. Immunology</source><volume>2</volume><fpage>945</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1038/nri955</pub-id><pub-id pub-id-type="pmid">12461567</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nojima</surname><given-names>T</given-names></name><name><surname>Haniuda</surname><given-names>K</given-names></name><name><surname>Moutai</surname><given-names>T</given-names></name><name><surname>Matsudaira</surname><given-names>M</given-names></name><name><surname>Mizokawa</surname><given-names>S</given-names></name><name><surname>Shiratori</surname><given-names>I</given-names></name><name><surname>Azuma</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo</article-title><source>Nature Communications</source><volume>2</volume><elocation-id>465</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms1475</pub-id><pub-id pub-id-type="pmid">21897376</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlmutter</surname><given-names>RM</given-names></name><name><surname>Hansburg</surname><given-names>D</given-names></name><name><surname>Briles</surname><given-names>DE</given-names></name><name><surname>Nicolotti</surname><given-names>RA</given-names></name><name><surname>Davie</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Subclass restriction of murine anti-carbohydrate antibodies</article-title><source>Journal of Immunology</source><volume>121</volume><fpage>566</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">79606</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pone</surname><given-names>EJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Mai</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>CA</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Sakakura</surname><given-names>JK</given-names></name><name><surname>Patel</surname><given-names>PJ</given-names></name><name><surname>Al-Qahtani</surname><given-names>A</given-names></name><name><surname>Zan</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway</article-title><source>Nature Communications</source><volume>3</volume><elocation-id>767</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms1769</pub-id><pub-id pub-id-type="pmid">22473011</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puffer</surname><given-names>EB</given-names></name><name><surname>Pontrello</surname><given-names>JK</given-names></name><name><surname>Hollenbeck</surname><given-names>JJ</given-names></name><name><surname>Kink</surname><given-names>JA</given-names></name><name><surname>Kiessling</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Activating B cell signaling with defined multivalent ligands</article-title><source>ACS Chemical Biology</source><volume>2</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1021/cb600489g</pub-id><pub-id pub-id-type="pmid">17432821</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickert</surname><given-names>RC</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Roes</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice</article-title><source>Nature</source><volume>376</volume><fpage>352</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/376352a0</pub-id><pub-id pub-id-type="pmid">7543183</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>LJ</given-names></name><name><surname>Stein</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny</article-title><source>Journal of Immunology</source><volume>141</volume><fpage>4352</fpage><lpage>4356</lpage><pub-id pub-id-type="pmid">3143762</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybin</surname><given-names>VO</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Sabri</surname><given-names>A</given-names></name><name><surname>Elouardighi</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>E</given-names></name><name><surname>Steinberg</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Stimulus-specific differences in protein kinase C delta localization and activation mechanisms in cardiomyocytes</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>19350</fpage><lpage>19361</lpage><pub-id pub-id-type="doi">10.1074/jbc.M311096200</pub-id><pub-id pub-id-type="pmid">14970215</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Santos-Valente</surname><given-names>E</given-names></name><name><surname>Klaver</surname><given-names>S</given-names></name><name><surname>Ban</surname><given-names>SA</given-names></name><name><surname>Emminger</surname><given-names>W</given-names></name><name><surname>Prengemann</surname><given-names>NK</given-names></name><name><surname>Garncarz</surname><given-names>W</given-names></name><name><surname>Müllauer</surname><given-names>L</given-names></name><name><surname>Kain</surname><given-names>R</given-names></name><name><surname>Boztug</surname><given-names>H</given-names></name><name><surname>Heitger</surname><given-names>A</given-names></name><name><surname>Arbeiter</surname><given-names>K</given-names></name><name><surname>Eitelberger</surname><given-names>F</given-names></name><name><surname>Seidel</surname><given-names>MG</given-names></name><name><surname>Holter</surname><given-names>W</given-names></name><name><surname>Pollak</surname><given-names>A</given-names></name><name><surname>Pickl</surname><given-names>WF</given-names></name><name><surname>Förster-Waldl</surname><given-names>E</given-names></name><name><surname>Boztug</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ</article-title><source>Blood</source><volume>121</volume><fpage>3112</fpage><lpage>3116</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-10-460741</pub-id><pub-id pub-id-type="pmid">23319571</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Santos-Valente</surname><given-names>E</given-names></name><name><surname>Keller</surname><given-names>B</given-names></name><name><surname>Warnatz</surname><given-names>K</given-names></name><name><surname>Boztug</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Protein kinase C δ: a gatekeeper of immune homeostasis</article-title><source>Journal of Clinical Immunology</source><volume>36</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1007/s10875-016-0323-0</pub-id><pub-id pub-id-type="pmid">27541826</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>G</given-names></name><name><surname>Khan</surname><given-names>AQ</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Snapper</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands</article-title><source>Journal of Immunology</source><volume>175</volume><fpage>3084</fpage><lpage>3091</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.5.3084</pub-id><pub-id pub-id-type="pmid">16116197</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>TAY</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role of antigen receptor affinity in T cell-independent antibody responses in vivo</article-title><source>Nature Immunology</source><volume>3</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1038/ni776</pub-id><pub-id pub-id-type="pmid">11896394</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The microbiome in SLE pathogenesis</article-title><source>Nature Reviews. Rheumatology</source><volume>15</volume><fpage>72</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/s41584-018-0152-z</pub-id><pub-id pub-id-type="pmid">30607012</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slack</surname><given-names>J</given-names></name><name><surname>Der-Balian</surname><given-names>GP</given-names></name><name><surname>Nahm</surname><given-names>M</given-names></name><name><surname>Davie</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency</article-title><source>The Journal of Experimental Medicine</source><volume>151</volume><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1084/jem.151.4.853</pub-id><pub-id pub-id-type="pmid">6966310</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snapper</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Differential regulation of protein- and polysaccharide-specific Ig isotype production in vivo in response to intact Streptococcus pneumoniae</article-title><source>Current Protein &amp; Peptide Science</source><volume>7</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.2174/138920306778017972</pub-id><pub-id pub-id-type="pmid">16918444</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavnezer</surname><given-names>J</given-names></name><name><surname>Guikema</surname><given-names>JEJ</given-names></name><name><surname>Schrader</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mechanism and regulation of class switch recombination</article-title><source>Annual Review of Immunology</source><volume>26</volume><fpage>261</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090248</pub-id><pub-id pub-id-type="pmid">18370922</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Distinctive activation mechanisms and functions for protein kinase Cdelta</article-title><source>The Biochemical Journal</source><volume>384</volume><fpage>449</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1042/BJ20040704</pub-id><pub-id pub-id-type="pmid">15491280</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>CL</given-names></name><name><surname>Wilson</surname><given-names>TJ</given-names></name><name><surname>Strauch</surname><given-names>P</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Pelanda</surname><given-names>R</given-names></name><name><surname>Torres</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response</article-title><source>The Journal of Experimental Medicine</source><volume>207</volume><fpage>1485</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1084/jem.20092695</pub-id><pub-id pub-id-type="pmid">20566717</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>TH</given-names></name><name><surname>Nakata</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Begum</surname><given-names>NA</given-names></name><name><surname>Shinkura</surname><given-names>R</given-names></name><name><surname>Fagarasan</surname><given-names>S</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Nagaoka</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers</article-title><source>Nature Immunology</source><volume>11</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1038/ni.1829</pub-id><pub-id pub-id-type="pmid">19966806</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidyanathan</surname><given-names>B</given-names></name><name><surname>Yen</surname><given-names>WF</given-names></name><name><surname>Pucella</surname><given-names>JN</given-names></name><name><surname>Chaudhuri</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>AIDing chromatin and transcription-coupled orchestration of immunoglobulin class-switch recombination</article-title><source>Frontiers in Immunology</source><volume>5</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00120</pub-id><pub-id pub-id-type="pmid">24734031</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Bülow</surname><given-names>GU</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name><name><surname>Bram</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulation of the T-independent humoral response by TACI</article-title><source>Immunity</source><volume>14</volume><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(01)00130-3</pub-id><pub-id pub-id-type="pmid">11371359</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watashi</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Iwamoto</surname><given-names>M</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Uchida</surname><given-names>N</given-names></name><name><surname>Daito</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>K</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name><name><surname>Kiyohara</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Aizaki</surname><given-names>H</given-names></name><name><surname>Wakita</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>31715</fpage><lpage>31727</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.501122</pub-id><pub-id pub-id-type="pmid">24025329</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>EP</given-names></name><name><surname>Manickam</surname><given-names>A</given-names></name><name><surname>Ponniah</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>B cell development and activation defects resulting in xid-like immunodeficiency in BLNK/SLP-65-deficient mice</article-title><source>Ternational Immunology</source><volume>12</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1093/intimm/12.3.397</pub-id><pub-id pub-id-type="pmid">10700474</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zan</surname><given-names>H</given-names></name><name><surname>Pone</surname><given-names>EJ</given-names></name><name><surname>Mai</surname><given-names>T</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immunoglobulin class-switch DNA recombination: induction, targeting and beyond</article-title><source>Nature Reviews. Immunology</source><volume>12</volume><fpage>517</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1038/nri3216</pub-id><pub-id pub-id-type="pmid">22728528</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>MY</given-names></name><name><surname>Cisalpino</surname><given-names>D</given-names></name><name><surname>Varadarajan</surname><given-names>S</given-names></name><name><surname>Hellman</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>HS</given-names></name><name><surname>Cascalho</surname><given-names>M</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>Núñez</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens</article-title><source>Immunity</source><volume>44</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.006</pub-id><pub-id pub-id-type="pmid">26944199</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72116.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.07.20.453051" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.07.20.453051"/></front-stub><body><p>Although how structurally different antigens can activate B-lymphocytes to produce IgG with or without T cell help has been a long-standing question, this manuscript provides a clue to this important issue.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72116.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Yasuda</surname><given-names>Tomoharu</given-names></name><role>Reviewer</role><aff><institution>Hiroshima University</institution></aff></contrib><contrib contrib-type="reviewer"><name><surname>Wienands</surname><given-names>Jurgen</given-names></name><role>Reviewer</role><aff><institution>Georg August University Goettingen</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.07.20.453051">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.07.20.453051v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Protein kinase Cδ is essential for the IgG response against T cell-independent type 2 antigens and commensal bacteria&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Carla Rothlin as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Tomoharu Yasuda (Reviewer #1); Jurgen Wienands (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) As PKCδ is known as a key signaling molecule suppressing autoimmune diseases. Important role of PKCδ in TI-2 response may suggest that homeostatic TI-2 response possibly influence on suppression of autoimmune diseases. Though authors briefly mentioned about autoimmunity in p 24, line 430-434, discussion may not be enough. For example, Michel Nussenzweig's group reported that critical role of Lyn in the regulation of clonal expansion and terminal differentiation of B cells in TI-2 responses (Shih et al., Role of antigen receptor affinity in T cell-independent antibody responses in vivo., Nat. Immunol., 3, 399, 2002). Since Lyn-deficient mice show autoimmune diseases similar to PKCδ-deficient mice (Nishizumi et al., Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice., Immunity, 3, 549, 1995), both Lyn and PKCδ may regulate same signaling pathway. Including further discussion related between TI-2 antigen/BCR signal and autoimmunity will enhance discussion.</p><p>2) Why and how is PKCδ required differently downstream of TI-2 BCR crosslinking but not in TD antigen exposure? It would be nice if authors discuss about this point.</p><p>3) How do IL-1α/β and IFNα regulate Aicda gene expression in synergy with BATF? It would be nice if authors discuss about transcriptional regulation of Aicda based on past reports.</p><p>4) How do TI-2 antigens engage PKC-δ? Is it solely the configuration or clustering of the BCR (as hypothesized in the Discussion part) or do secondary signals add to this and to the BATF-AID axis as suggested by the results of the forced expression of BATF to substitute for the loss of PKC-δ?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1) PKCδ is known as a key signaling molecule suppressing autoimmune diseases. Important role of PKCδ in TI-2 response may suggest that homeostatic TI-2 response possibly influence on suppression of autoimmune diseases. Though authors briefly mentioned about autoimmunity in p 24, line 430-434, discussion may not be enough. For example, Michel Nussenzweig's group reported that critical role of Lyn in the regulation of clonal expansion and terminal differentiation of B cells in TI-2 responses (Shih et al., Role of antigen receptor affinity in T cell-independent antibody responses in vivo., Nat. Immunol., 3, 399, 2002). Since Lyn-deficient mice show autoimmune diseases similar to PKCδ-deficient mice (Nishizumi et al., Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice., Immunity, 3, 549, 1995), both Lyn and PKCδ may regulate same signaling pathway. Including further discussion related between TI-2 antigen/BCR signal and autoimmunity will enhance discussion.</p><p>2) Why and how is PKCδ required differently downstream of TI-2 BCR crosslinking but not in TD antigen exposure? It would be nice if authors discuss about this point.</p><p>3) How do IL-1α/β and IFNα regulate Aicda gene expression in synergy with BATF? It would be nice if authors discuss about transcriptional regulation of Aicda based on past reports.</p><p>4) Figure 1C, 2B; Concentration unit should be converted to ng/ml same with other figures for IgM and IgG.</p><p>5) Figure 1C-E; NP-Ficoll stimulation in the absence of cytokines will be helpful to know background levels otherwise it is difficult to know the impact of IL-1 and IFNα in class switch recombination and antibody secretion.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1) A key aspect of this manuscript is the specificity with which PKC-δ is involved in TI-2 antigen responses as opposed to TD-dependent responses. In fact, Figure 2A and others suggest that PKC-δ activation is not an all-or-nothing event. Hence, the specificity or kinetic of PKC-δ activation could be corroborated. One important set of data is shown in Supplementary Figure 3. Why is the IgM response so strongly increased in the absence of PKC-δ?</p><p>2) How do TI-2 antigens engage PKC-δ? Is it solely the configuration or clustering of the BCR (as hypothesized in the Discussion part) or do secondary signals add to this and to the BATF-AID axis as suggested by the results of the forced expression of BATF to substitute for the loss of PKC-δ? The arrow head downstream of cytokine and TOLL-like receptors ends diffusely somewhere at the BATF-Aicda axis (Figure 7).</p><p>3) In other publications that describe the generation and analysis of PKC-δ-deficient mouse mutants such differences were not observed or less obvious. Is there an explanation to these differences?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72116.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) As PKCδ is known as a key signaling molecule suppressing autoimmune diseases. Important role of PKCδ in TI-2 response may suggest that homeostatic TI-2 response possibly influence on suppression of autoimmune diseases. Though authors briefly mentioned about autoimmunity in p 24, line 430-434, discussion may not be enough. For example, Michel Nussenzweig's group reported that critical role of Lyn in the regulation of clonal expansion and terminal differentiation of B cells in TI-2 responses (Shih et al., Role of antigen receptor affinity in T cell-independent antibody responses in vivo., Nat. Immunol., 3, 399, 2002). Since Lyn-deficient mice show autoimmune diseases similar to PKCδ-deficient mice (Nishizumi et al., Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice., Immunity, 3, 549, 1995), both Lyn and PKCδ may regulate same signaling pathway. Including further discussion related between TI-2 antigen/BCR signal and autoimmunity will enhance discussion.</p></disp-quote><p>We assume that dysregulation of microbiota due to the defective TI-2 response may cause autoimmunity, in conjunction with the defect of B-cell tolerance in PKCδ-deficient mice, as previously suggested in another mouse model (Manfredo Vieira et al., 2018); the defect of homeostatic production of the anti-bacterial IgG3 (Figure 6) may allow tissue translocation of some gut bacteria, which may in turn trigger autoantibody production in PKCδ-deficient mice. We have now included further discussion about this possibility (page 16, line 362-375).</p><p>It was shown that PKCδ is dispensable for BCR-stimulated activation and proliferation of B cells but is necessary to make self-reactive B cells unresponsive to the BCR stimulation (Mecklenbräuker et al., 2002). It was also reported that PKCδ exerts pro-apoptotic activity in normal peripheral B cells through nuclear translocation, unless BAFF signaling reverses it (Mecklenbräuker et al., 2004). On the other hand, Src-family tyrosine kinases including Lyn are redundantly required for BCR signal transduction, such as phosphorylation of key signaling molecules such as Igα/β and CD19. In addition, Lyn is also responsible for phosphorylation and activation of inhibitory co-receptors for BCR such as CD22 and FcγRIIb, which is the basis for spontaneous activation and exaggerated responses of B cells leading to autoimmunity in Lyn-deficient mice. Therefore, the mechanism for the induction of autoimmunity in PKCδ-deficient mice appears quite different from that in Lyn-deficient mice. Also, IgG production in response to TI-2 Ag or bacteria has not been studied in Lyn-deficient mice. Thus, we have not referred to Lyn-deficient mice in this manuscript.</p><disp-quote content-type="editor-comment"><p>2) Why and how is PKCδ required differently downstream of TI-2 BCR crosslinking but not in TD antigen exposure? It would be nice if authors discuss about this point.</p></disp-quote><p>As previously appreciated, a role of BCR signaling is substantially different between TI-2 and TD responses: Tyrosine kinases Btk and an adaptor molecule BLNK, for example, are necessary for TI-2, but not TD, immune response (as we wrote in page 2, the second paragraph). Unlike TI-2 antigen, TD antigen alone cannot induce proliferation, IgM production, and Batf expression in naive B cells, as we demonstrated in <italic>in-vitro</italic> study (Figures 1A, 1B, 5B, Figure 5 —figure supplement 1A). Thus, it appears that TD antigen-mediated BCR signaling cannot exceed a threshold for B-cell activation including sufficient phosphorylation of PKCδ (Figure 2A) required for class switching to IgG; T-cell-derived signals are known to compensate for the defective BCR signaling in the TD response. We have now included this discussion in the Discussion section (page 14, line 313-321).</p><p>We still don’t know how PKCδ is activated and exert its function after BCR crosslinking by TI-2 antigen. The phosphorylation of Thr 505 and Ser 647 of PKCδ, known to be important for its enzymatic activity, was observed in unstimulated naïve B cells and unchanged by TI-2 antigen stimulation in our <italic>in-vitro</italic> system (data not shown), but that of Tyr 311 was augmented, which is known to alter its intracellular localization and the substrate specificity (Rybin et al., 2004; Steinberg, 2004). Thus, identification of the substrate of PKCδ in B cells after stimulation with TI-2 antigen would be an important next step. We have now included this discussion (page 13, line 290 – page 14, line 312).</p><disp-quote content-type="editor-comment"><p>3) How do IL-1α/β and IFNα regulate Aicda gene expression in synergy with BATF? It would be nice if authors discuss about transcriptional regulation of Aicda based on past reports.</p></disp-quote><p>It has been shown that the transcription of <italic>Aicda</italic> requires the activation of the 5’ upstream enhancer region of <italic>Aicda</italic> locus, in addition to the recruitment of BATF to the 3’ downstream region in the context of TD response (Tran et al., 2010; Vaidyanathan et al., 2014). Therefore, we consider that the secondary stimulation such as IL-1α/β and IFNα might signal to activate the 5’ upstream enhancer region and induce the transcription of <italic>Aicda</italic> in synergy with BATF induced by TI-2 antigen stimulation. We have now described about this hypothesis in detail in the Discussion section (page 14, line 325 – page 15, line 340).</p><disp-quote content-type="editor-comment"><p>4) How do TI-2 antigens engage PKC-δ? Is it solely the configuration or clustering of the BCR (as hypothesized in the Discussion part) or do secondary signals add to this and to the BATF-AID axis as suggested by the results of the forced expression of BATF to substitute for the loss of PKC-δ?</p></disp-quote><p>We have not investigated how TI-2 antigen-bound BCR engages PKCδ. It would be challenging to study the relation between the configuration or clustering of BCR and the engagement/activation of PKCδ, which would require a specialized technology such as TIRF microscopy. As we have shown in the revised manuscript, TI-2 antigen alone could induce PKCδ phosphorylation and <italic>Batf</italic> expression, but IL-1α/β or IFNα alone could not, nor they could augment the TI-2 antigen-induced these responses (Figure 5B, the newly added ‘Figure 5 —figure supplement 1B-D’). Therefore, we consider that TI-2 antigen activates the PKCδ-BATF axis solely through BCR. We suppose that this signaling axis and the secondary signals may merge on the <italic>Aicda</italic> locus to induce AID expression as described in our response to the Essential Revisions 3. We have mentioned about the new data in the Result section (page 10, line 204-206).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1) As I commented in Public review, PKCδ is known as a key signaling molecule suppressing autoimmune diseases. Important role of PKCδ in TI-2 response may suggest that homeostatic TI-2 response possibly influence on suppression of autoimmune diseases. Though authors briefly mentioned about autoimmunity in p 24, line 430-434, discussion may not be enough. For example, Michel Nussenzweig's group reported that critical role of Lyn in the regulation of clonal expansion and terminal differentiation of B cells in TI-2 responses (Shih et al., Role of antigen receptor affinity in T cell-independent antibody responses in vivo., Nat. Immunol., 3, 399, 2002). Since Lyn-deficient mice show autoimmune diseases similar to PKCδ-deficient mice (Nishizumi et al., Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice., Immunity, 3, 549, 1995), both Lyn and PKCδ may regulate same signaling pathway. Including further discussion related between TI-2 antigen/BCR signal and autoimmunity will enhance discussion.</p></disp-quote><p>This is the same comment as in the Essential Revisions 1, to which we have answered.</p><disp-quote content-type="editor-comment"><p>2) Why and how is PKCδ required differently downstream of TI-2 BCR crosslinking but not in TD antigen exposure? It would be nice if authors discuss about this point.</p></disp-quote><p>This is the same comment as in the Essential Revisions 2, to which we have answered.</p><disp-quote content-type="editor-comment"><p>3) How do IL-1α/β and IFNα regulate Aicda gene expression in synergy with BATF? It would be nice if authors discuss about transcriptional regulation of Aicda based on past reports.</p></disp-quote><p>This is the same comment as in the Essential Revisions 3, to which we have answered.</p><disp-quote content-type="editor-comment"><p>4) Figure 1C, 2B; Concentration unit should be converted to ng/ml same with other figures for IgM and IgG.</p></disp-quote><p>We have revised the Figure 2B to use ng/ml for IgM concentration. To measure IgG3 titers in the experiments shown in Figure 1C and other figures, we used serum of a C57BL/6 mouse as a standard, and therefore the values were shown as relative units (AU). It would not mean anyway if we had measured absolute values of the IgG3 concentrations; the values cannot be compared among the figures, since the number of cultured cells and the culture period varied among the figures, depending on the situation of each experiment such as the number of available mice.</p><disp-quote content-type="editor-comment"><p>5) Figure 1C-E; NP-Ficoll stimulation in the absence of cytokines will be helpful to know background levels otherwise it is difficult to know the impact of IL-1 and IFNα in class switch recombination and antibody secretion.</p></disp-quote><p>We have added back the data of stimulation with antigen alone in the revised Figure 1C-E. Consequently, the data previously shown as Figure 1 —figure supplement 1F has been removed since it has been integrated into the new Figure 1E.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1) A key aspect of this manuscript is the specificity with which PKC-δ is involved in TI-2 antigen responses as opposed to TD-dependent responses. In fact, Figure 2A and others suggest that PKC-δ activation is not an all-or-nothing event. Hence, the specificity or kinetic of PKC-δ activation could be corroborated. One important set of data is shown in Supplementary Figure 3. Why is the IgM response so strongly increased in the absence of PKC-δ?</p></disp-quote><p>As this comment is essentially integrated in the Essential Revisions 2, please look at our response written there. In particular, we admit that TD-antigen stimulation modestly and transiently increased the PKCδ phosphorylation at Tyr 311 (Figure 2A) but did not induce Batf expression at all (Figure 5B, Figure 5 —figure supplement 1A). Therefore, the extent of PKCδ phosphorylation might not be enough to exceed the activation threshold.</p><p>We think the increased IgM response in the TD immune response of PKCδ-deficient mice reflects the reported constitutive pro-apoptotic activity of PKCδ in the peripheral B cells (Mecklenbräuker et al., 2004) that may normally limit the initial proliferation of B cells in the TD immune response. We have mentioned this possibility in the Discussion section (page 13, line 294 – page 14, 307).</p><disp-quote content-type="editor-comment"><p>2) How do TI-2 antigens engage PKC-δ? Is it solely the configuration or clustering of the BCR (as hypothesized in the Discussion part) or do secondary signals add to this and to the BATF-AID axis as suggested by the results of the forced expression of BATF to substitute for the loss of PKC-δ? The arrow head downstream of cytokine and TOLL-like receptors ends diffusely somewhere at the BATF-Aicda axis (Figure 7).</p></disp-quote><p>This is the same comment as in the Essential Revisions 4, to which we have answered.</p><disp-quote content-type="editor-comment"><p>3) In other publications that describe the generation and analysis of PKC-δ-deficient mouse mutants such differences were not observed or less obvious. Is there an explanation to these differences?</p></disp-quote><p>Although we have carefully searched for the literature, we could not find any studies analyzing immune responses or class-switching in PKCδ-deficient mice. Most of the studies were focused on B cell tolerance.</p></body></sub-article></article>